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INTRODUCTION 
Ectopic Proteins (General Comments) 
The "ectopic" production of polypeptide hormones and other proteins 
by malignant tumors from a variety of tissues seems now to be well-
established (1, 2, 3). These proteins are synthesized by tumors derived 
from tissue not normally engaged in their production and include alpha-
fetoprotein (4), ACTH (5), carcinoembryonic antigen (6), calcitonin (7), 
parathyroid hormone (8), human placental lactogen (9), placental alkaline 
phosphatase (10), human chorionic gonadotropin (11), isoferritins (12), 
as well as other isoenzymes (13), polypeptides (14), and cell-surface 
proteins. Tumors may produce and secrete a single or multiple ectopic 
polypeptide hormones but usually do not synthesize steroids, an event 
which would require the sequential action of several enzymes. More­
over, certain types of tumors tend to produce a particular peptide or 
hormone (14, 15, 16). For instance, bronchial carcinomas often produce 
parathormone-like material, hepatomas commonly secrete alphafetoprotein, 
oat cell carcinomas tend to produce ACTH, MSH, or antidiuretic hormone, 
and carcinoembryonic antigen is often associated with carcinomas but 
less frequently with leukemia or lymphomas. 
Although not all tumors exhibit this property, the fact that cancer 
cells originating from a variety of tissues have been shown to elaborate 
a spectrum of ectopic products and that these often are characteristic 
of a particular tumor suggests the use of these proteins as possible 
indicators of neoplasia. The clinical measurement of these proteins 
circulating in the blood has been used as a biochemical marker for 
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malignancy and as a monitor for the success of surgery, radiation, and 
chemotherapy. The rationale is simply stated: if the synthesis of these 
proteins is normally restricted to embryonic life, then their later 
detection in a male or nonpregnant female should provide a specific 
and sensitive marker for neoplasm. Although the true incidence of these 
markers and their specificity for cancer remain uncertain, partly 
because of differences in methodology in various laboratories and dif­
ferences in the patient populations studied, these tumor-associated 
polypeptides are likely to play an important role in the future diagnosis 
of cancer. The search for more reliable markers including surface 
antigens, ectopic hormones, or isoenzymes is currently an area of active 
research. 
The monitoring of ectopic proteins in the circulation for use as 
tumor markers may require detection of very low levels of the proteins. 
This can be achieved using sensitive radioimmunoassays (RIÂ) which can 
detect minute quantities of hormone as well as protein fragments, pre­
cursors, and other biologically inactive molecules. 
To account for the phenomenon of ectopic protein expression, it 
has been widely proposed that neoplastic transformation is associated 
with derepression of the genome, resulting in dedifferentiation and the 
expression of normally silent genes (17, 18). However, molecular 
hybridization experiments in which cDNAs prepared from poly (A)-
containing mRNA from both normal and transformed cells were cross-
hybridized suggest that the great majority of mRNA species in trans­
formed cells are present in normal cells, though the relative num­
bers of copies may be greater in transformed cells (17, 19, 20, 21). 
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Thus, differing patterns of gene expression in normal and neoplastic 
cells which is manifest in the appearance of ectopic products may be 
due more to modulation of preexisting gene activity rather than to 
development of new genes by oncogenic viruses or the derepression of 
silent genes. 
Although an alteration in the genetic material of tumor cells pro­
ducing extraneous proteins could account for some instances of ectopic 
products, it is inconsistent with those cases in which close chemical 
similarities have been observed between the ectopic and authentic 
hormones (22). It is possible that the synthesis of an inappropriate 
product may be caused by a change in gene expression accompanying the 
malignant transformation. In this regard, it is of interest that many 
of the ectopic products are fetal proteins or products of the developing 
placenta. The ectopic synthesis of placental proteins in human cancer 
is of special interest because of similarities between neoplastic and 
embryonic cells. 
Distinguishing between normal and ectopic forms of a given protein 
may aid in diagnosing a neoplastic condition. Moreover, the chemical 
analysis of ectopic products may aid in understanding their mechanism of 
synthesis. Thus, in several instances, the molecular characterization 
of ectopic products has been carried out. Results suggest that ectopic 
and eutopic hormones are often quite similar (23, 24), at least when 
analyzed by radioimmunoassay or radioreceptorassay. However, more 
discriminating techniques have shown differences in isoelectric points, 
electrophoretic mobility, and carbohydrate content (25). Gel exclusion 
chromatography has revealed high molecular weight forms of several 
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proteins isolated from tumor tissue or secreted into tissue culture 
media (25, 26). It is suggested that these high molecular weight 
species may be precursor forms which do not undergo maturation in the 
tumor cells (27). In addition, partially purified alpha glycoprotein 
hormone subunits of ectopic origin have been shown to be deficient in 
recombination with authentic beta subunits (28). In this respect, 
the similarity among gastric carcinoid tumor, bronchogenic carcinoma, 
and HeLa alpha subunits (25) raises the possibility that the characteristics 
of tumor alphas may reflect abnormalities in neoplastic protein synthesis 
or carbohydrate attachment, which results in polypeptides with similar 
chemical and immunologic properties but with differences in physical 
and recombining properties. 
The human placenta is a complex multifunctional endocrine organ 
that supports fetal survival and development. Placental functions in 
vitro have usually been studied by using expiants and primary cultures, 
which are difficult to establish and cannot be maintained for a long 
time in tissue culture. Synthesis of placental hormones by expiants or 
primary cultures declines because the cells dedifferentiate in culture. 
Choriocarcinoma cells, malignant cells derived from the placenta, have 
been used extensively as a model system to study placental functions 
(29, 30, 31, 32). These cells do not, however, control the synthesis of 
certain proteins as does the normal placenta. The level of human 
chorionic gonadotropin often is higher in patients with chorio­
carcinoma than it is in women during normal pregnancy. Since the regula­
tion of hCG synthesis in choriocarcinoma cells may differ from that in 
normal placenta, it is necessary to establish another type of placental 
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cell to study placental function. Chou (33) has, therefore, established 
human placental cells transformed by Simian Virus 40 (SV40). Regula­
tion of the synthesis of a and p subunits plus hCG in these transformed 
human placental cells differed from the regulation in choriocarcinoma 
cells as will be discussed below. 
Human Chorionic Gonadotropin (hCG) 
This study will focus on two ectopic products, chorionic gonadotropin 
and the placental isozyme of alkaline phosphatase and, thus, a brief 
description of these proteins follows. 
Human chorionic gonadotropin is a glycoprotein tropic hormone 
normally synthesized by the placenta; it is composed of two nonidentical 
subunits o? and g (34), having molecular weights of 14,900 and 23,000, 
respectively (35, 36). The two chains are bonded noncovalently (37, 38). 
The amino acid sequences and carbohydrate side chains for alpha and beta 
have been determined by Bahl (39) and Morgan et al. (40). The hormone 
is a glycoprotein containing about 30% by weight carbohydrate (35, 36). 
In recent years, it has been demonstrated that among the human glyco­
protein hormones: follicle stimulating hormone (FSH), luteinizing hor­
mone (LH), thyroid stimulating hormone (TSH), and chorionic gonadotropin 
(hCG), the beta subunit is specific and confers biological activity on 
the hormone, while the alpha subunit is nearly identical for each of 
the four hormones (34, 37, 41, 42). 
Several investigators have established that the site of synthesis 
of the hormone is the syncytiotrophoblastic cells of the placenta (43). 
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It functions during pregnancy to convey a signal from the placenta to 
the corpus luteum which results in the maintenance of this tissue 
and an Increased synthesis of steroid hormones (44, 45). During preg­
nancy, the serum and urine levels of hCG rise continuously during the 
first 10-12 weeks and then declines to a lower level in the last half 
of gestation (43, 46). This suggests that the control of hormone pro­
duction is coupled to placental development. 
Human chorionic gonadotropin is not normally present in the circula­
tion of nonpregnant females but may be present in normal testis (47, 
48). However, it is found in patients with choriocarcinoma (49), 
hydatidiform mole (50), and other tumors that ectopically synthesize the 
hormone (23, 51). In addition, the ectopic production of both the free 
alpha and beta subunits has been demonstrated in serum from patients with 
various carcinomas (23, 52, 53). The ectopic synthesis of hCG has also 
been described in continuous cultures of cells originally isolated from 
a bronchogenic carcinoma (53). Subsequent cloning of these cells pro­
duced lines in which unbalanced synthesis of both alpha and beta sub-
units has been observed (54). 
Placental Alkaline Phosphatase (PAP) 
The human alkaline phosphatases are a heterogeneous set of enzymes 
which catalyze the cleavage of orthophosphate from monophosphate esters 
at alkaline pH. They are glycoproteins and show marked organ specificity, 
and several distinct gene loci appear to be involved in determining their 
primary structures (55, 56, 57, 58, 59). Several lines of evidence 
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suggest that at least three separate structural loci are concerned in 
determining the protein portion of the different alkaline phosphatase 
enzymes ; one coding for the placental enzyme, at least one coding for 
the intestinal enzyme, and at least one locus for the bone, liver, and 
kidney forms of the enzyme (60, 61, 62, 63). Several common electro-
phoretic variants of placental alkaline phosphatase have been identified 
and shown to be attributable to alleles at an autosomal locus (64). 
The intestinal, liver, bone, and kidney enzymes do not show such variants 
and are presumably determined by some other locus (or loci) (57). They 
can be distinguished from each other on the basis of various properties 
including heat stability (65, 66, 67, 68), electrophoretic mobility (57), 
sialic acid content (69, 70, 71), inhibition by certain L-amino acids 
(62), and immunoreactivity (59, 72, 73, 74, 75). 
It is generally believed that the locus determining the placental 
forms is, in the normal individual, expressed only in placenta (55). 
However, ectopic or aberrant expression of this locus occurs in certain 
cancers of various other tissues, and this has usually been attributed 
to derepression of the locus arising in some way from the malignant 
process (10, 76, 77, 78, 79, 80). The best-known example of this is 
HeLa (77, 81, 82, 83, 84). Benham and Harris (85) presented evidence for 
the expression of placental alkaline phosphatase locus in endocervix 
and in cervical mucus from a series of nonpregnant women who did not 
have cervical malignancy. Thus, the placental alkaline phosphatase 
locus was expressed in nonmalignant endocervix. The result is of some 
significance in connection with the widely held view that the expres­
sion of placental alkaline phosphatase in certain malignancies is due 
8 
to derepression of a locus for a fetal enzyme protein normally re­
pressed in adult tissues. 
There is evidence for heterogeneity of alkaline phosphatase expres­
sion among the different sublines of HeLa now in existence, although all 
the cell lines were originally derived from one culture (82, 85). 
Possible causes for this heterogeneity, e.g., somatic mutation or 
altered regulatory mechanisms have been considered. This heterogeneity 
is also found in the intestinal alkaline phosphatase between the fetal 
and adult forms (61). It may represent the expression of different 
gene loci or a difference in post-translationa1 modification. 
Several reports have described the modulation of various alkaline 
phosphatase activities in an effort to understand the factors con­
trolling selective expression of alkaline phosphatase in cultured 
cells and to ultimately understand the phased expression of alkaline 
phosphatase in normal placenta and that which occurs during malignant 
transformation (86, 87). The induced alkaline phosphatase from a 
SV40 tsA30 mutant-transformed term placental cell line resembled first 
trimester placental alkaline phosphatase (liver type) in physicochemical 
and immunological properties (88). It is of particular interest that 
adrenal glucocorticoids induce alkaline phosphatase activity in em­
bryonic intestinal epithelium of chicks and mice earlier than it nor­
mally appears during development (89, 90, 91). Apparently, it re­
sults from an increase in the catalytic efficiency of this enzyme and 
is not accompanied by a new synthesis of enzyme protein (92). 
Alkaline phosphatase In HeLa cells provides a useful system for 
studying the mechanism of cellular enzyme regulation. In the presence 
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of glucocorticoids, HeLa lines with a low basal level of alkaline 
phosphatase exhibit a dramatic Increase In total alkaline phospha­
tase activity (89, 93). 
Induction of Ectopic Proteins 
The exogenous effect of sodium butyrate on Induction 
Butyric acid, a 4-carbon fatty acid, occurs naturally in the body 
and is formed by the hydrolysis of ethylbutyrate. The role of butyric 
acid in cellular function is poorly understood. Recent studies on 
mammalian cells in culture suggest that this fatty acid affects the 
morphology (94), growth rate, and biochemical properties of cells 
(95). HeLa cells are normally round or polygonal with few elongated 
cells. When these cells are incubated in the presence of 2.5 mM sodium 
butyrate, filamentous protrusions begin to appear after 7 to 8 hr, and 
by 14 hr, have developed into long spikes (96). The morphological 
alterations of HeLa cells induced by sodium butyrate are prevented by 
actinomycin D (0.5 pg per ml) or cyclohexlmide (10 tig per ml). Ap­
parently the syntheses of some new RM and protein are required to 
produce morphological changes (96). Alternatively, actinomycin D and 
cyclohexlmide may directly affect the same reactions that are in­
fluenced by sodium butyrate. 
Pace et al. (97) were the first to show that sodium butyrate at 
higher concentrations (10 mM and above) is toxic to human cells in 
culture. Sodium butyrate reverslbly inhibits the proliferation of HeLa 
cells, shutting off DNA synthesis, but affecting cell viability only 
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slightly K98). The mechanisms of action of sodium butyrate on various 
cell lines are unknown. Wright (99) has suggested two possibilities: 
(a) sodium butyrate may affect the growth rate and morphology of Chinese 
hamster ovary cells, in part, by altering adenylate cyclase activity 
and thereby increasing the cAMP level that inhibits DNA, synthesis in 
Gg-phase and prevents subsequent mitosis (100, 101); and (b) cell 
morphology is somewhat dependent upon the lipid content of the cell 
surface, so that an incorporation of sodium butyrate into the lipid 
components of the surface membrane may actually alter the membrane 
configuration, and thereby, the cell morphology. No data were presented 
to substantiate either possibility. 
Recently, Riggs et al. (102) reported on the ability of sodium 
butyrate to produce a shift from the parental and monoacetyl derivative 
of histone % to highly modified forms, thus offering a means for 
studying their properties more effectively. The hyperacetylation is 
due to inhibition of histone deacetylase (103). In general, the in­
crease in acetylation of the basic chromosomal proteins appears to 
precede any increase in nuclear RNA synthesis. Thus, histone acetyla­
tion signals a change in the fine structure of the chromatin and in the 
capacity of DNA to serve as a template for RNA synthesis (104, 105). 
It is of particular interest to compare the effect of sodium 
butyrate on the proliferating malignant Friend erythroleukemia cell and 
on the proliferating HeLa cell, which is also derived from a malignant 
cell. In the Friend cell, differentiation is normally blocked (102). 
Sodium butyrate Induces the continuation of differentiation and the 
production of specific products such as globin as well as a striking ac­
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cumulation of acetylated histones. Whether there is a causal relation­
ship between histone acetylation and the observed differentiation is not 
known. Moore and Chalkley (106) using cultured hepatoma cells suggest 
an interdependence of the level of histone H4 acetylation and the rate 
of cell division. However, in hepatoma tissue culture cells, the in­
creased amount of histone acetylation is maximal 6-12 hr after administra­
tion of sodium butyrate, but the protein patterns made during this 
period did not show any significant differences on two-dimensional gel 
electrophoresis (107). The results suggest that cellular protein 
synthesis and inhibition of cell division are independent of sodium 
butyrate-induced hyperacetylation. Treatment of Chinese hamster ovary 
cells for 24 hr with increasing sodium butyrate concentration also 
leads to dephosphorylation of histone HI and the enhancement of an HI-like 
protein, as well as the hyperacetylation of histone H4 (108). More­
over, prëtreatment of cells with sodium butyrate, which increases histone 
acetylation, selectively increases the susceptibility of histone H3 to 
phosphorylation by a protein kinase (109). This event is Ca -dependent. 
Sodium butyrate may also be useful as a general tool to study the 
regulation of growth and differentiation of mammalian cells in culture. 
This compound has been shown to induce hCG-a and PAP syntheses in certain 
tumor cell lines (110, 111, 112, 113). 
HeLa cells, derived from a carcinoma of the cervix, was the first 
continuous human tissue culture line to be established vitro (114), 
and has been a primary source for the study of human cell biology. 
It is interesting that the heteropioid HeLa cell line after many years 
in culture produces several proteins normally found only during embryonic 
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development or synthesized by specialized cells. For example, these 
cells produce the placental form of alkaline phosphatase (115), and the 
addition of iron to culture media stimulates the synthesis by HeLa cells 
of an apoferritin with properties different from the adult form of this 
protein (116). More recently, it has been observed that certain strains 
of HeLa also synthesize and secrete human chorionic gonadotropin and the 
free ot- and p-subunits (27, 111). The accumulation of hCG-p in HeLa 
cell cultures is enhanced markedly by growth in medium containing sodium 
butyrate. Since this peptide hormone is not degraded in cell culture, 
it seems that the synthesis of hCG is increased by butyrate (54). 
Since hCG is a eutopic hormone for trophoblastic tumors, but an 
ectopic hormone for nontrophoblas tic tumors, its synthesis by the two 
types of tumors might be regulated differently. Chou et al. (110) 
compared the synthesis of hCG and hCG-a by three choriocarcinoma cell 
lines with the synthesis by two nontrophoblas tic tumor-derived cell 
lines — ChaGo and HeLa. They also tested the effects of sodium butyrate 
on the synthesis. They found that in the absence of inducer, all of the 
cell lines can produce hCG-a, the trophoblastic tumor cells at roughly 
comparable rates, but the nontrophoblastic tumor cells at widely different 
rates. Sodium butyrate has strikingly different effects on the two 
classes of tumor cells: it induces synthesis of hCG-a and hCG in the 
nontrophoblas tic tumor cells, but represses it in the trophoblastic 
tumor cells. Thus, these data indicate that the regulation of hCG and 
hCG-of production differs in placental and nonplacental tumors. It is 
reported that sodium butyrate also induced pituitary follicle stimulating 
hormone (FSH) in HeLa cells (117). Thus, it was suggested that the genome 
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of HeLa cells is derepressed for highly differentiated gene products 
as well as oncofoetal proteins. 
On the other hand, there are several reports that sodium butyrate 
affects membrane functions to cause the change in cell morphology 
in HeLa cells. Sodium butyrate caused an increase in cellular 
sialyllactosylceramide content by elevating CMP-sialic acid: 
lac tosyIceramide sialyltrans feras e activity in HeLa cells without 
significantly affecting other glycosyltransferase activities ; (118) . 
Induction of sialyltransferase activity is blocked by cycloheximide or 
actinomycin D. This is the first report on the induced synthesis of 
glycolipid components by sodium butyrate. In addition, butyrate stimu­
lates ganglioside biosynthesis (119) and induces Cholera toxin 
(choleragen) as well as g-adrenergic receptors, which are coupled to 
adenylate cyclase in HeLa cells (120, 121). Thus, butyrate appears to 
induce several biochemical changes in plasma membranes of HeLa cells 
and these changes have different kinetics and dose dependencies. 
In this regard, butyrate may be a useful inducer of differentiation to 
explore the biosynthesis, assembly, and functioning of membrane com­
ponents . 
Sodium butyrate as well as several short-chain fatty acids produced 
an increase in alkaline phosphatase activity in hybrid B-6 cells (mouse 
X Chinese hamster cell hybrids) (122). Sodium butyrate at 2 to 5 mM 
exhibits the greatest activity. Studies on the inducer activity-
structure relationship revealed the necessity of a carboxyl and an 
ethyl or longer alkyl group. It is evident that the alkaline phosphatase-
inducing activity of these short-chain fatty acids is not correlated 
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to the length of their carbon chains but seems to be related to the 
growth inhibitory effect to some degree. This induction by sodium 
butyrate is observed in several other cell lines including HeLa cells 
(123). In animal tissues, short-chain fatty acids are generally present 
in small amounts, coupled with coenzyme A, as intermediates in the 
degradation and synthesis of long-chain fatty acids (124). It is un­
known, however, if exogeneous short-chain fatty acids are metabolized 
by the cultured cells used here. Since p-phenylpropionic acid, a 
chemical probably nonmetabolized by cultured mammalian cells has an 
inducing activity, it is reasonable to conclude that short-chain 
fatty acids act on the cell without being converted to other active 
endogeneous inducers. 
Sodium butyrate seems unlikely to activate alkaline phosphatase 
because its addition to cell-free extracts prepared from untreated cul­
tures led to no increase in specific activity. The enzyme assay of a 
mixture of cell free extracts from cultures grown with and without 
sodium butyrate ruled out the presence of activator(s) and inhibitor(s). 
It is, therefore, suggested that the induction is caused by an in­
crease in the concentration of alkaline phosphatase protein, or by an 
increased catalytic efficiency of the preexisting enzyme, as interpreted 
by Cox et al. (92) on the induction mechanism of alkaline phosphatase 
by hydrocortisone in HeLa cells. 
The effects of other exogenous DNA synthesis inhibitors on induction 
Sodium butyrate has been shown to inhibit DM synthesis in HeLa^  ^
cells (125). Recent studies have shown that other well-characterized 
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inhibitors of DNA synthesis that are used as anti-neoplastic agents 
(hydroxyurea, methotrexate, and l-P-D-arabinofuranosylcytosine) also 
increase hCG synthesis (92, 111) and the activity of oncofoetal alkaline 
phosphatase (126). 
Hydroxyurea which is a specific inhibitor of DNA but not RNA 
synthesis in HeLa^  ^cells was widely studied for its capacity to in­
duce the ectopic proteins in several cell lines including HeLa (117, 
125, 127). Hydroxyurea is believed to exert its biological ef­
fects primarily through inhibition of ribonucleoside diphosphate reduc­
tase, an essential enzyme for production of all four deoxynucleotides 
(128, 129). Hydroxyurea also stimulated FSH production and was syner­
gistic with sodium butyrate (117). This unexpected synthesis of FSH led 
to studies on the related pituitary hormone, lutropin (LH). LH produc­
tion by HeLa cells was increased up to 300-fold by growth in medium with 
butyrate. Hydroxyurea and methotrexate also increase LH synthesis and 
potentiate the effects of sodium butyrate on induction (130). The 
production of a presumptive pituitary gonadotropin (LH) by a non-
pituitary cell is unexpected and suggests that butyrate and certain 
anti-neoplastic drugs that inhibit DNA. synthesis may derepress the HeLa 
cell genome for differentiated functions. 
Cytosine arabinoside (ara-C) has been reported to be incorporated 
into DNA (22, 131, 132) and to cause chromosome breakage in mammalian 
cells (133, 134, 135). Ara-C is an S-phase specific agent (136, 137) 
and its active metabolite, the triphosphate ara-CTP, is an inhibitor of 
DNA replication in a variety of viral, bacterial, and mammalian models 
(138, 139, 140). Several hypotheses have been proposed for the 
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inhibitory effect of ara-CTP on DNA synthesis. One hypothesis is that 
ara-CTP inhibits DNA polymerase by competing with dCTP for binding to 
this enzyme (141). Another hypothesis is the inhibition of DNA synthesis 
through incorporation of ara-C into the DNA strands (142). This could 
result in chain termination, slowing of chain elongation, and/or the 
formation of abnormal DNA (143). The incorporation of ara-C into DN^  
is one mechanism responsible for producing lethal cellular events 
(144). Ara-C does not deplete cellular dNTP pools (141, 145), ara-C 
nucleotides are only weak inhibitors of ribonucleotide reductase (146),. 
and ara-CTP is an efficient inhibitor of vitro DNA, replication 
systems where dNTPs are supplied (147, 148, 149, 150). Even though 
the precise mode of action of ara-C remains controversial, ara-C is 
an effective agent in the treatment of acute myelogenous leukemia in 
man (151, 152). 
Glutamine synthetase activity in chick embryonic neural retina has 
been reported to be stimulated by cytosine arabinoside, and the increase 
in activity could be blocked by prior addition of actinomycin D (153). 
However, further study has convincingly demonstrated that inhibition of 
DNA synthesis is not causally related to the induction of glutamine 
synthetase (154). Concentrations of ara-C that inhibit DNA synthesis 
are 2 to 3 logs lower than those required to induce glutamine synthetase. 
Furthermore, other inhibitors of DNA synthesis such as MTX, hydroi^ rea, 
and 5-fluorodeoxyuridine failed to induce glutamine synthetase. The 
high dose of cytosine arabinoside apparently inhibits RNA synthesis suf­
ficiently to block a regulator of glutamine synthetase while allowing 
transcription and translation of this enzyme. 
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It has also been reported that concentrations of ara-C which In­
hibit the synthesis of DNÂ induce alkaline phosphatase in cultured 
human choriocarcinoma cells (127). In this system, it has been sug­
gested that ara-C acts by altering DNA structure. Ghosh et al. (155) 
have shown that the ectopic synthesis by HeLa cells of hCG as well 
as the fetal form of alkaline phosphatase was increased by ara-C. 
It is not known whether ara-C inhibits DNA, synthesis without affecting 
DNA structure in HeLa cells. Ara-C also acted synergistically with 
butyrate in causing morphologic changes in the cells and increasing 
APase activity and synthesis of hCG (156). 
Thymidine (Thd) arrests cells at the G^ -S stage of their growth 
cycle by inhibiting the deoxyribonucleotide reductase conversion of 
CDP to dCDP (157). Generally, more than 10 dThd is required to ar­
rest normal cells, but a significant number of tumor cell lines are 
arrested or killed by dThd concentrations as low as 10 ^ M. The ap­
parent selective effect of dThd on tumor cells vitro suggests that 
dThd might be useful as a chemotherapeutic agent in the treatment of 
sensitive tumors (158). 
The inhibition of thymidylate synthetase by the monophosphate of 
5-fluoro-2'-deoxyuridlne or 5-fluorouracil is very advantageous for 
cancer chemotherapy (159). In fact, 5-fluoro-2*-deoxyuridlne (FdUrd) 
is a much less toxic and more potent drug than 5-fluorouracil. 
Goz (160) has shown that 5-iodo-2'-deoxyuridine (IdUrd) will 
Increase HeLa cell alkaline phosphatase activity. However, it was 
found that parathyroid hormone (PTH) could block the induction by both 
hydrocortisone and IdUrd (161). Thus, PTH seems to have a similar effect 
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on both the normally high rate of production of alkaline phosphatase 
and the high levels of alkaline phosphatase activity in HeLa cells in­
duced by hydrocortisone orldUrd. PTH is known to increase cAMP concentra­
tion in both kidney and bone by stimulating adenyl cyclase (162). It 
has been found that other compounds known to be inhibitors of cAMP 
phosphodiesterase or known to be stimulators of adenyl cyclase also 
inhibit induction of alkaline phosphatase activity in HeLa cells by 
hydrocortisone and IdUrd (163, 164). It may be speculated on the basis 
of this information that cAMP is somehow involved in the inhibition of 
induction by all these agents since all may potentially increase the 
concentration of cAMP in HeLa cells. 
The mechanism of induction has been related to a decreased 
phosphate content in alkaline phosphatase in steroid treated cells 
(165), but there is also evidence that it might reflect some general 
alterations in the plasma membrane. Some support for the latter as­
sumption comes from an observation (166) of a shift in distribution of 
alkaline phosphatase in steroid-treated HeLa cells toward association 
with more dense plasma membrane fractions. A recent paper (167) has 
reported evidence that there is a measurable difference between 
the tumor and placental membrane-bound enzyme, that is, membranes 
of tumor origin bound significantly more peroxidase-labeled 
antibody than did placental membranes. It is likely either that 
the enzyme is more exposed in the cancer cell membrane or that it is 
more susceptible to becoming exposed. Moreover, it was reported that 
JAR choriocarcinoma cell alkaline phosphatase was highly hydrophobic 
as determined by octyl agarose chromatography and appeared to be larger 
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than the placental isoenzyme based on gel filtration and polyacrylamide 
gel electrophoresis (168). More recently, results from another labora­
tory (169) have provided more specific evidence for the involvement of 
membrane phospholipids in regulation of alkaline phosphatase activity. 
It was shown that alkaline phosphatase activity in both particulate and 
solubilized preparations from HeLa cells was affected by phospholipase 
Ag or by the product of its activity, i.e., lysophosphatidylcholine. A 
rapid increase in alkaline phosphatase activity also occurred following 
the treatment of HeLa^ g cells with the Rosenthal's inhibitor (RI) 
which is an inhibitor of phospholipase activity (170). However, this 
stimulatory effect was dependent on the presence of bovine serum in the 
medium. It is likely that the effect of Rosenthal's inhibitor is based 
on direct interaction with plasma membrane rather than on the inhibitory 
effect of this compound on phospholipase A^ . Thus, it is important to 
consider the membrane microenvironment as an important controlling factor 
for a variety of membrane associated enzymes. It is also possible that 
the elevation of alkaline phosphatase in HeLa cells by glucocorticoids 
constitutes only one element in a more general pattern of plasma membrane 
perturbations. This could include both lipid and carbohydrate components 
of the plasma membrane. Considerable evidence has been obtained con­
cerning sialic acid composition of steroid treated HeLa cells (171, 
172). Perhaps, even more significant are the reports demonstrating the 
involvement of sialic acid and phospholipids in the uptake and binding 
of glucocorticoids by cultured animal cells. 
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Thymidylate synthetase requires methylene tetrahydrofolate as 
a reductant and the reduction of dihydrofolate is an important 
part of the process. Such a folic acid analogue as methotrexate (N^ -^
methyl-4-amino-4-deoxyfolic acid) is among the most useful anticancer 
drugs. Methotrexate (MTX) is a potent inhibitor of dihydrofolate reduc­
tase, which is essential for biosynthesis of thymidine. It is those 
doses of MTX that can be shown to inhibit DNA synthesis but that do not 
inhibit RNA synthesis that stimulates hCG synthesis and placental akla-
line phosphatase activity in cultured choriocarcinoma cells (173). 
This effect of methotrexate can be blocked by simultaneous addition 
of thymidine or folinic acid, neither of which alone increases human 
chorionic gonadotropin synthesis or placental alkaline phosphatase 
activity in these cells. The mechanism by which the inhibition of DM 
synthesis might cause an increase in hCG and placental alkaline 
phosphatase is not known. From the result mentioned above, how­
ever, the possibility that the stimulation is related to inhibition 
of DNA synthesis cannot be ruled out. Wiltshaw and Moloney 
(174) have previously reported that leukocyte alkaline phosphatase 
activity from patients with chronic myelogenous leukemia or pyogenic 
infections can be stimulated with both aminopterin and amethopterin 
(MTX). MTX gave better stimulation than aminopterin. This stimulation 
could be blocked by folinic acid if added with the inhibitors. Metho­
trexate also increases lutropin (LH) synthesis and potentiates the ef­
fects of sodium butyrate on induction of LH in HeLa cells (175). 
5-Bromo-2'-deoxyuridine (BrdUrd) has been used for the past several 
years as a tool in the study of the regulation of differentiated gene 
I 
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functions (176). In some tissue and cell culture systems, such as 
chick chondrocytes (177, 178), erythroblast precursor cells (179, 
180), HTC cells (181, 182), and mammary epithelial cells (183), the 
expression of differentiated functions is inhibited by exposure to BrdUrd. 
However, BrdUrd in other systems can Induce a differentiated state. 
Schubert and Jacob (184) induced mouse neuroblastoma differentiation 
in vitro with BrdUrd and this induction was not blocked by a number of 
inhibitors of DNA synthesis, suggesting that the halogenated nucleoside 
need not be incorporated into DNA to alter the phenotype of neuroblastoma 
cells. They argued that BrdUrd caused a metabolic change in the cell 
which indirectly induced the differentiation by Increasing the af­
finity between the limiting membrane of the cell and the surface of the 
cultured dish. On the other hand, Koyama and Ono (185, 186) reported 
that the BrdUrd-induced alkaline phosphatase activity in a mouse/ 
Chinese hamster hybrid cell line did not take place when the nucleo­
side was added to the culture with thymidine, DNA synthesis inhibitors 
(hydroxyurea and cytosine arabinoside), an RNA synthesis inhibitor 
(actinomycin-Sg), or a protein synthesis inhibitor (cycloheximide). 
It is generally accepted that to exert an effect on differentiation, 
the nucleoside must be incorporated into the DNA and that the BrdUrd-
substituted DNA acts in a way that the rate of transcription of genes 
responsible for the synthesis of specialized products characteristic 
for differentiation is changed. 
It has been determined by autoradiographic studies (177) and DNA 
buoyant density centrifugation (181, 187) that BrdUrd is incorporated 
into the DNA of the cell as a structural analog of thymidine. In those 
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studies BrdUrd did not act as a mutagen because its effects were re­
versible. When BrdUrd is removed from the growth medium, differentiated 
functions return (188, 189). Moreover, if thymidine is included in the 
medium, the effect of BrdUrd can be prevented (probably by competing 
with the analogue for incorporation into cellular DM) (189). These 
facts are consistent with, but not proof of, the hypothesis that BrdUrd 
exerts its effect from a site within the DNA. Bulmer et al. (190) 
examined the mechanism by which BrdUrd produces changes in the alkaline 
phosphatase levels in mammalian cells in culture. They reported some 
similarities between the action of BrdUrd and the hormone hydrocortisone 
and suggested that the BrdUrd has its effect after its incorporation 
into DNA. 
In several human heteroploid cell lines (e.g., H.Ep 2), which have 
relatively low constitutive alkaline phosphatase levels, simultaneous 
exposure of the cells to both BrdUrd and hydrocortisone resulted in no 
greater induction than that observed with either drug alone. Experi­
ments utilizing mitomycin C yielded significant induction in the 
presence of this agent alone, and somewhat less induction when both 
mitomycin C and BrdUrd were added simultaneously (190). These results 
suggest that DNA synthesis is required for BrdUrd-mediated induction of 
alkaline phosphatase (191a). 
Choriocarcinoma cells are characterized by abnormally high hCG 
production. In these cells, sodium butyrate and BrdUrd inhibited the 
synthesis of hCG and hCG-a, whereas dibutyryl cyclic AMP (BtgCAMP) 
stimulated their synthesis (191b). In contrast to choriocarcinoma cells, 
cultures of SV40-transformed placental cells increased their synthesis 
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of hCG-!3 plus hCG and hCG-o? in the presence of sodium butyrate (33). Al­
though BtgCANP induced the synthesis of hCG-a in these transformed 
cells, it did not affect the synthesis of hCG-P plus hCG. BrdUrd, on 
the other hand, did not affect the synthesis of either peptide in these 
cells. 
Alkaline phosphatase can also be induced in cultured human chorio­
carcinoma cells by addition of 1-P-D-arabinofuranosylcytosine (ara-C), 
mitomycin C, and phleomycin, all of which are known to alter DNA struc­
ture (127). As mentioned above, ara-C has been reported to be in­
corporated into DM (131, 132, 192) and to cause chromosome breakage 
in mammalian cells (133, 134, 135). Phleomycin, a copper-containing 
/ 
antibiotic, binds to DNA in A-T rich regions (193). Mitomycin C alters 
the backbone of DNA by producing interstrand cross-links in DNA of 
bacterial (194, 195, 196) and animal cells (197, 198). Since these 
inducers also inhibit DNA synthesis. Chou and Robinson (127) did control 
experiments with hydroxyurea (199) and thymidine (200), which inhibit 
the synthesis of DNA without affecting its structure. They found 
that only those compounds which alter DNA structure induced alkaline 
phosphatase in choriocarcinoma cells. They also presented evidence 
that butyrate and inhibitors of DNA synthesis act through different 
mechanisms since their effects are additive or synergistic. However, 
1-P-D-arabinofuranosylcytosine inhibited the induction by sodium 
butyrate. RNA synthesis and protein synthesis were required for 
induction. 
Wicks et al. (201) have found that, in rat hepatoma, tyrosine 
aminotransferase and phosphoenolpyruvate carboxykinase are induced 
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by derivatives of cyclic 3',5'-AMP. Only those derivatives which could 
be shovm to inhibit DNA synthesis would Induce the two enzymes. It is 
not clear whether the induction of tyrosine aminotransferase and phos-
phoenolpyruvate carboxykinase and the inhibition of DNA synthesis are 
related. 
Hyperosmolarity causes both an increase in alkaline phosphatase 
activity and a decrease in growth rate of T24 cells (derived from a 
human urinary bladder carcinoma). 
Wheatley (202) has shown that DNA synthesis in HeLa is inhibited 
by hyperosmolarity and Nitowsky et al. (203) found that hyperosmolarity 
would stimulate HeLa alkaline phosphatase. Under the influence of 
hyperosmolarity, the heat-stable enzyme in HeLa cells is significantly 
increased while the heat-labile component is markedly reduced in KB 
cells (204, 205). The increase in placental alkaline phosphatase 
activity by hyperosmolarity is particularly intriguing since hyperosmo­
larity can also inhibit DNÂ synthesis. Whether these two events are 
related is completely unknown. 
The possible mechanism of ectopic protein synthesis 
Differentiated gene expression in eukaryotic cells appears, in 
certain instances, to be associated with cessation of cell multiplica­
tion (206). Sodium butyrate Inhibits HeLa cell proliferation and 
decreases DNA synthesis (95, 96). Ectopic synthesis of the fetal 
(carcinoplacental) form of alkaline phosphatase (APase) by HeLa cells 
was increased by sodium butyrate, propionate, pentanoate, and hexanoate 
(155, 207). Other aliphatic monocarboxylates did not induce APase, and 
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protein synthesis was required for APase induction. Since APase inducers 
also inhibited cellular multiplication, the hypothesis was suggested 
that inhibition of cell growth may be a prerequisite for APase induction. 
This hypothesis was supported by the findings that some inhibitors of 
DNA synthesis such as hydroxyurea, methotrexate, and ara-C also in­
creased hCG synthesis (125) as well as APase activity (188). These 
inhibitors of DNA synthesis acted synergistically with butyrate in 
causing morphologic changes in the cells and increasing APase activity 
and hCG synthesis. 
Ghosh et al. (156) suggest that butyrate and certain anti­
neoplastic drugs that inhibit DNA synthesis may derepress the HeLa 
cell genome for differentiated functions. Thus, modulation of gene 
expression in HeLa cells may be related to the inhibition of DNA 
synthesis caused by butyrate and other compounds. There is, however, 
no available evidence as yet to indicate that these phenomena are cor­
related. For these reasons, this thesis will examine the possible 
relationship of DNA synthesis inhibition to the ectopic production of 
hCG and PAP in HeLa cells. In particular, the concentration-dependence 
and kinetics for protein induction and DNA synthesis inhibition in 
response to various compounds will be determined. A correlation 
between the two events might be suggested if the following criteria are 
met: 1) those concentrations of a particular agent which inhibit DNA 
synthesis must also produce a marked increase in hCG subunit levels and 
alkaline phosphatase activity; 2) the kinetics of DNA synthesis inhi­
bition must coincide or precede an increase in protein production. 
Moreover, by examining the production of three different ectopic 
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products (hCG-o, hCG-p, PAP) in a single cell line in response to 
various Inducers, it may be possible to determine whether these proteins 
are regulated In a coordinate fashion. It will be useful to examine 
the combined effects of sodium butyrate and other DNÂ synthesis inhibi­
tors on ectopic protein induction to determine whether they cause induc­
tion ; via similar or different mechanisms. Moreover, the induced cy-subunit 
and PAP will be partially characterized to determine whether they are 
similar to the HeLa uninduced proteins or their placental counterparts. 
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MATERIALS AND METHODS 
Materials 
Crude human chorionic gonadotropin (hCG) was purchased from Organon, 
Inc. (West Orange, NJ) and purified and dissociated into subunlts as 
described previously (34). Purified a and P subunlts were prepared by 
R. Canfield and supplied by the NIH (lot CR 123). Purified p subunlt 
was also purchased from Calblochem. Macromomycin and cesalln were ob­
tained through the courtesy of Dr. Rex Montgomery, Department of Bio­
chemistry, University of Iowa. Aphldlcolln was a gift from Drs. B. 
Hesp and A. H. Todd, Imperial Chemical Industries Limited, Pharmaceuticals 
Division,(Manchester, England). Sodium butyrate was purchased from 
Matheson Coleman and Bell, and Sigma Chemical Co. supplied hydroxyurea, 
cytosine arabinoside hydrochloride, (+)-amethopterIn (methotrexate), 
5-fluorodeoxyurldine, thymidine, phosphonoformlc acid, mitomycin C, 
ethldlum bromide, acrldlne, bleomycin sulfate, cycloheximlde, and 
actinomycln D. For the alkaline phosphatase experiments, Sigma Chemical 
Co. supplied phosphatase substrate, disodlum p-nitrophenyl phosphate, 
and alkaline phosphatase (placental form) as well as the inhibitors of 
alkaline phosphatase such as L-leucine, L-phenylalanine, L-homoarginlne 
hydrochloride, L-phenylalanylglycylglycine, and EDTA. Bovine serum albu­
min for protein assay by Lowry et al. (207) was also purchased from Sigma 
Chemical Co. P-L Blochemlcals, Inc. supplied 5-bromodeoxyuridine. 
Lyophillzed trypsin-TPCK was purchased from Worthington Biochemical 
Corporation. New England Nuclear was the source of all radioisotopes 
3 3 including [methyl- H] thymidine (77.0 Ci/mmol), [ H(G)] deoxyadenoslne 
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(20.3 Ci/nmol), [5,6-^ H] uridine (42.3 Ci/mmol), and L-[3,4,5-Vn)] 
leucine (95 Ci/nmol). Culture media and serum were obtained from 
2 2 Grand Island Biological Co. and disposable 25 cm and 75 cm T-flasks 
were purchased from Corning. 
Methods 
Spinner cell culture 
HeLa cells obtained through the courtesy of Norm Cooper and 
Dr. Bernard Moss at the National Institutes of Health were maintained 
in spinner culture in RPMI-1640 tissue culture medium with 0.2% sodium 
bicarbonate and supplemented with 0.06% L-glutamine, 7% fetal calf 
serum or calf serum, 80 units/ml of penicillin, and 20 pg/ml of 
streptomycin sulfate. Everyday cell numbers were counted with a 
hemocytometer and the culture was diluted with fresh RPMI-1640 medium 
so that the cell concentration was not less than 3 x 10^  cells/ml. 
Monolayer cell culture 
O 
HeLa cells were plated in RPMI-1640 medium into 75 cm culture 
flasks and grown at 37° under 5% CO^  in a humidified incubator. 
Every other day, the cultures were replaced with fresh culture 
medium. When cells were nearly confluent, medium was decanted from 
culture flasks and trypsin-EDTA solution (0.005% trypsin in Hank's 
balanced salt solution (HBSS) without CaClg and MgSO^  and 0.02% EDTA) 
was added to detach the cells from the monolayer. The detached cells 
were split into two flasks and supplemented with RPMI-1640 medium; 
this propagation was continued until spinner cells were needed. In 
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general, 5 plates of monolayer cultures were trypslnized and gathered 
in the spinner flask containing about 100 ml of RFMI-1640 medium. 
Purification of hCG-g and -B subunits 
Crude human chorionic gonadotropin was obtained commercially 
(Organon, Inc.)* Purification was achieved as described (34) by 
chromatography of the crude material on DEAE Sephadex A-50 in 0.01 M 
TriS'Cl (pH 8). The material eluting at 0.1 M NaCl was further puri­
fied by successive chromatography on Sephadex G-75 and G-150 in 0.1 M 
NH^ HCO^ . Purity of the final product was determined by electrophoresis 
on polyacrylamide gels containing sodium dodecyl sulfate (SDS-PÂGE). 
Subunits were obtained by incubating the hormone at 40° for 1 hr in 
10 M urea (pH 4.5) followed by chromatography on DEAE Sephadex-A25 in 
0.03 M glycine (pH 7.5) containing 8 M urea. Under these conditions, 
the alpha subunit does not bind to the column and the beta subunlt can 
be eluted with 0.2 M glycine (pH 7.5) containing 8 M urea and 1 M NaCl. 
Purity of the subunits was confirmed by SDS-PAGE. Molecular weights ob­
served were in good agreement with published values determined by 
physical measurements (35, 36); 24,500 for alpha and 37,500 for beta. 
Antisera preparation 
Immunization of rabbits with hCG-a and complete Freunds adjuvant 
was performed according to standard immunologic techniques. The antigens 
had been purified to homogeneity (as judged by SDS-polyacrylamide gel 
electrophoresis) from commercial preparations of hCG (Organon, Inc.). 
An aliquot of purified a (0.75 ml containing 1.95 mg of protein) was 
Injected intramuscularly (i.m.) into a New Zealand rabbit (~ 8 lb 
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female) In 0.75 ml of complete Freunds adjuvant. After 6 months, 96 pi 
of saline containing 500 M>g of purified o^ subunlt was mixed with 500 pi 
of Incomplete Freunds adjuvant and Injected subcutaneously (s.c.). 
Animals were bled by cardiac puncture prior to immunization and 7-9 
days following booster inoculations. About 40 ml of blood was drawn 
and left to coagulate overnight at 4°. The clot was removed by . 
centrlfugatlon. The resulting antlsera showed no cross reactivity 
with an unrelated hormone, placental lactogen, no cross reactivity with 
hCG-p, and 2.7% cross reactivity with holo hCG. 
Induction protocol 
When cell culture experiments were performed, cells from stock 
2 2 
spinner culture were plated in RPMI-1640 medium into 25 cm or 75 cm 
5 flasks at a density of about 10 cells/ml and growth was continued at 
37° under 5% CO^  in a humidified Incubator until cells were nearly 
confluent, generally two or three days. At that time, media were re­
placed and where indicated, DNA synthesis inhibitors, butyrate, and/or 
radioisotopes were added. Appropriate volumes of DNA synthesis in­
hibitors were added from concentrated stock solutions as indicated 
In the table and figure legends. Most solutions of DNA synthesis 
inhibitors were prepared by dissolving in distilled HgO. Other 
solvents used to prepare stock solutions of several drugs are sum­
marized in Table XII. After dissolving compounds in proper solvent, 
all solutions were filtered through autoclaved mllllpore filters 
(0.45 pm pore). After incubation of cultures with compounds tested 
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in this study, the media and cells were assayed for alpha and beta 
subunits of hCG and alkaline phosphatase as described below. 
Preparation of cell extracts 
Medium was aspirated from the culture flasks and cleared of de­
tached cells by centrifugation at 2,000 x g for 10 min. The cell sheet 
was removed from the flask by trypsinization (0.005% trypsin in HBSS 
and 0.02% EDTA). Cells were washed in 50 mM Tris « Cl (pH 7.4) buffer 
containing 0.9% (w/v) NaCl, resuspended in 1 ml of 50 mM Tris«Cl (pH 
7.4), and disrupted on ice by sonication with a Branson Bonifier 
(microtip, setting 6, 1-2 min, 50% duty cycle). The resulting 
sonicates were centrifuged at 15,000 x g for 20 min and the super­
natant fluid (lysate) was assayed for PAP as described below. Protein 
was determined by the method of Lowry et al. (207) using bovine serum 
albumin as standard. 
Incorporation of radioisotopes 
Cells were grown to a high density, in 24-well cluster plates or 
25 cm^  flasks after which time the medium was replaced with 1 ml or 5 ml 
of fresh RPMI-1640 medium containing 7% dialyzed fetal calf serum or 
calf serum, 80 units/ml of penicillin, and 80 pg/ml of streptomycin 
sulfate, 1 liCi/ml of either [^ H] thymidine (77 Ci/mmol), [^ H] deoxy-
adenosine (20.3 Ci/mmol), [^ H] uridine (42.3 Ci/mmol), or [%] leucine 
(95 Ci/mmol), and/or the amounts of butyrate, DNA synthesis inhibitors, 
actinomycin D, and cycloheximide as indicated in the table and figure 
3 3 legends. [ H] Deoxyadenosine was used instead of [ H] thymidine 
for radioisotope incorporation into cell cultures v^ ich were treated 
32 
with FdUrd, thymidine, or 5-bromo-2'-deoa^ uridine because these 
substrate analogues would compete for [ H] thymidine Incorporation. 
At the desired time, media were pipetted off, the cell sheet was re­
moved by trypsinization, and extracts prepared as described above. 
Nucleic acids and protein were precipitated from 0.5 ml of cell sonicate 
by the addition of an equal volume of cold 10% trichloroacetic acid. 
The precipitates were collected on nitrocellulose filters (HLllipore, 
0.45 pm), washed with 15 ml of cold 5% trichloracetic acid, dried, and 
counted in toluene scintillation fluid. Counting efficiency was 39% 
for The scintillation fluid contained 5 g of 2,5-diphenylo%azole 
(PPG) and 0.25 g of 1,4-bis[2-(5-phenyloxazolyl)]-benzene (POPOP) per 
liter of toluene. 
Alpha and beta radioimmnnnaaaay 
Purified alpha and beta were iodinated by the lactoperoxidase 
method as described by Roth (208). First, 15 yl of 0.05 M NaPi buffer 
(pH 7.4), 10 lAl of 0.4 M NaAc buffer (pH 5.6), and about 5 pg of protein 
(hCG-cy or -P) to be iodinated were added together into a tube. Then, 
125 10 nl of Na[ I] (0.5 mCi) was added into the above tube under the hood 
and 2 pi of bovine lactoperoxidase (2.7 mg/ml) in 0.1 M NaAc buffer 
(pH 5.6) and 2 pi of freshly diluted 30% hydrogen peroxide (0.002% 
final concentration) were added and incubated for 60 sec at room 
temperature. After incubation, 100 pi of a mixture containing 
16% (w/v) sucrose, 1% (w/v) KI, and 0.02% (w/v) NaN^  was added 
to stop the reaction. The iodination mixture was chromatographed 
on a G-lOO Sephadex column (0.9 x 110 cm) equilibrated with elution 
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buffer (0.05 M KPi buffer, pH 7.4 with 0.05% (w/v) BSA (RIA grade) 
125 
and 0.02% (w/v) NaN^ )• Fractions (1 ml) were checked for I 
by solid scintillation in a manual well-type y-counter. Only monomeric 
125 I-a or -p was used for radioimmunoassay (RIA). The labelled pro­
teins used had an average specific activity of 95 |J,Ci/p,g. Incubation 
mixtures for radioimmunoassay contained 0.1-0.5 ml of culture media, 
rabbit anti-alpha serum (1:10,000 final dilution) or rabbit anti-
beta serum (1:1,000 final dilution), 2 pi of normal rabbit serum, 
125 
I-labelled alpha or beta (approximately 50,000 cpm or 10,000 cpm, 
respectively), and 50 mM potassium phosphate buffer (pH 7.4) containing 
0.1% (w/v) bovine serum albumin to a final volume of 1 ml. Mixtures 
were incubated at room temperature for 16-20 hr at which time goat anti-
rabbit IgG serum was added and incubation continued at 37° until a 
visible precipitate formed. By preincubation of antiserum with samples 
125 
and standards prior to I-tracer addition (rather than simultaneous 
addition), the sensitivity of the assay was Increased to about 200 pg/ml. 
Instead of goat anti-rabbit IgG serum, protein A from aureus 
Cowan I strain can be used as the "2nd antibody." Protocol for making 
pickled aureus was obtained from E. D, Rosenblum, Department of 
Microbiology, Health Science Center, University of Texas, Dallas, 
Texas. A fresh slant from a stock culture of aureus Cowan I (ATCC 
12598) was set up overnight at 37°. About 250 ml of tryptlcase soy 
broth (TSB) was Inoculated with a few ml of the above slant washed 
into TSB and put on a shaker at 37° overnight. Multiples of TSB 
(500 ml) were Inoculated with 10 ml of the above broth and put on a 
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shaker at 37° for 16 hr. Contents of flasks were spun down at 10,000 
X g for 10 mln. Cells from all flasks were combined, suspended in PBS 
and spun down at 10,000 x g for 10 min. The cell pellet was resus-
pended in PBS to 10% (w/v) and concentrated formaldehyde was added 
slowly with stirring to a concentration of 1.5% and stirred for 1-1/2 
hr at room temperature. This suspension was centrifuged at 10,000 x g 
for 10 min. The cells were washed twice with PBS and resuspended to 
10% (w/v) suspension in the same buffer. Aliquots of 100 ml were 
placed in a 1-liter flask and swirled in an 80°C waterbath for exactly 
4 min and then immediately cooled on ice. This was repeated until the 
whole suspension had been processed. Cells were spun down at 10,000 
X g for 10 min and washed with PBS containing 0.02% NaNg. The above 
step was repeated and the 10% suspension in PBS containing 0.02% NaNg 
was kept at 40C. The procedure for the radioimmunoassay using this cell 
suspension as the "2nd antibody" was the same as that using goat anti-
rabbit IgG serum except for the omission of normal rabbit serum. Before 
using the cell suspension, it should be shaken well. Normally 200 m>1 
of cell suspension was sufficient to provide a large excess of protein 
A. The immune precipitates were collected by centrifugation and washed 
once with 1 ml of cold 50 mM potassium phosphate buffer (pH 7.4) con­
taining 0.1% bovine serum albumin and 0.1% Brij 58 detergent. The wash 
solution was combined with the original supernatant and counted along 
with the pellets in an automatic gamma counting system, model 4216 
operating with analyzer/sealer model 8725, Nuclear-Chicago Corporation 
(courtesy of Dr. Allen H. Trenkle, Department of Animal Science, 
ISU). 
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Partial purification of alkaline phosphatase 
Cell extracts (sonicated lysates) were incubated in 0.25 M sucrose 
and 20% (v/v) n-butyl alcohol at 37° for 1 hr, kept overnight at 4°, 
and centrifuged at 1,000 x g for 2 hr as described previously (209). 
The enzyme activity was recovered in the aqueous phase. The sediment 
was reextracted with butyl alcohol and centrifuged as before and the 
aqueous phase was pooled with that from initial extraction. Fractional 
acetone precipitation of the cell extracts was conducted at 4°. Enzyme 
was precipitated in the 60% acetone fraction. The precipitates were 
then suspended in 0.01 M Tris-Cl buffer, pH 7.4, and dialyzed free of 
butyl alcohol and acetone. 
Assay for alkaline phosphatase 
Alkaline phosphatase in cell extracts was assayed by the release 
of p-nitrophenol from p-nitrophenyl phosphate at pH 10.7 and 37° as 
described by Edlow et al. (210). To 0.9 ml of PAP cocktail (0.33 ml 
of 0.024 M p-nitrophenyl phosphate as substrate, 0.33 ml of 2.25 M 
2-amino-2-methyl-l-propanol, pH 10.7, and 0.24 ml of distilled HgO) 
was added 100 M-1 of cell lysate. The reaction mixture was incubated 
for 30 min in a 37° waterbath. The reaction was stopped by adding 
0.5 ml of 0.2 N NaOH and the absorbance of the mixture was read at 
400 nm. The activity of alkaline phosphatase was calculated as follows; 
units enzyme/ml lysate = A.^ n x x Protein concentration 400 mm 18.3 
of each lysate was less than 75 ^ g/ml. Conditions of protein concentration 
and time of incubation were chosen such that the increase in absorbance 
at 400 nm was proportional to the amount of activity present. One 
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unit is that activity catalyzing the hydrolysis of 1 imole of 
p-nitrophenyl phosphate per min at 37°. 
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RESULTS 
Specificity of Radioimmunoassay with Respect 
to the Free Subunits 
Since each of the free hCG subunits, a and g, had to be measured 
in the presence of the other, it was important to determine whether 
reactivity observed was intrinsic to each free subunit or resulted from 
cross reactivity between subunits. Thus, experiments were carried out 
to examine this possibility using particular antisera in this assay 
system. Figure 1 shows the specificity of the hCG immunoassay with 
respect to the free subunits. Free hCG-p was nonparallel with the 
hCG-of standard and displayed no cross reactivity at the midpoint of 
the dose-response curve, near where most measurements were made (Figure 
la). Free hCG-a was similarly nonparallel with hCG-p standard and 
displayed a cross reactivity of 0.85% (Figure lb). The above cross 
reactivity figures for free subunits in the gonadotropin radioimmuno­
assay probably represent overestimates, since it is known that subunit 
preparations may be contaminated with a small amount of undissociated 
hormone. However, the nonparallelismbetween free subunits a and p in 
these assays suggests that some of the reactivity may be intrinsic to 
each free subunit. The slope of the dose-response curve for authentic 
a-subunit (-0.0705) in the P-RIA was completely different from that 
for authentic g-subunit (-0.2929) (Figure 2). Authentic hCG-p as well 
as HeLa gl-subunits from unlnduced or butyrate-lnduced cells were not 
parallel to authentic a-subunlt in the 3 RIA. This suggests that the 
methodology in this study to assay each subunit of hCG in control or 
Figure 1. Specificity of gonadotropin radioimmunoassay with respect 
to the free subunits 
a. Cross-reactivity of hCG p-subunit (•) and hCG cy-subunit 
(o) with anti-ohCG serum in standard RIÀ 
b. Cross-reactivity of hCG subunit (•) and hCG P-subunit 
(o) with anti-phCG serum in standard R1Â 
Percent Tracer Precipitated Percent Tracer Precipitated 
8 
Figure 2. Dose-response curves for urinary hCG or-subunit and media from unlnduced and induced HeLa 
cells in the 8-subunit radioimmunoassay 
The ordinate is a log scale expressed as a percentage of the ^ ^^ I-labeled g-subunit 
tracer precipitated by anti-3 serum at a final dilution of 1:1000. The abscissa is a 
log scale denoting the ng of purified subunits or p.1 of HeLa media added to the RIÂ. 
Symbols : uninduced (•); butyrate-induced (A); hC6 orsubunit (o); hCG P-subunit (•). 
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Induced cultures can differentiate p-subunlt from cross reacting 
Cf-subunit. 
Effect of Sodium Butyrate on the Growth of 
HeLa Cells in Culture 
Sodium butyrate (3 mM) reverslbly inhibits the growth of HeLa S^  
cells and produces morphological changes such that the cells acquire a 
more fibroblast-like shape by greatly extending cellular processes. 
Figure 3 shows that the growth inhibition by sodium butyrate was signifi­
cant immediately after treatment. After 5 days incubation with sodium 
butyrate, cell numbers are decreased greatly. Thus, duration of most 
experiments in this study was about 3 days where cells stopped growth 
without significant cell death. 
Induction of hCG-a, -p, and PAP by Sodium Butyrate 
HeLa S^  cells produce low levels of @-subunlt (0.1 ~ 0.5 pg/mg 
protein) and subunit (<0.05 ng/mg protein) of hCG as well as the 
placental alkaline phosphatase (<0.05 mU/mg protein). Growth of 
cells in medium containing sodium butyrate for 72 hr markedly in­
creased the production of these proteins. The amount of these proteins 
produced by HeLa S^  cells depends on the concentration of sodium butyrate 
in the medium (Figure 4). The level of hCG-a as well as the activity 
of alkaline phosphatase were increased gradually from low concentra­
tions of sodium butyrate (0.25 mM) up to high concentrations (4 mM), 
where maximum induction occurred (10-fold for cy-subunit and 7.9-fold 
Figure 3. Effect of sodium butyrate on the growth of HeLa cells 
in culture 
2 Cells were plated in RPMI-1640 culture medium into 75 cm 
flasks at a density of about 10^  cells/ml. Sodium butyrate 
(3 mM) was added at the time of plating and growth was 
continued at 37° under 5% CO2 in a humidified incubator. 
At the times indicated, cells were trypsinized, washed in 
PBS buffer, and counted in a Coulter counter. 
Symbols: Control (o); sodium butyrate-treated (•). 
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Figure 4. Effect of sodium butyrate on the synthesis of hCG-a, hCG-p, PAP, and DNA in HeLa 
cell cultures 
When cells were confluent, cultures received fresh media containing the concentrations 
of sodium butyrate as indicated. After 72 hr, media and cells were collected and as­
sayed for alpha (#), beta (•), and PAP (A) as described in the Materials and Methods. 
For DNA synthesis inhibition (o), cells were grown in culture media containing the 
concentrations of sodium butyrate as indicated. After 72 hr, the cell sheets were 
washed with PBS buffer two or three times, covered with 5 ml of fresh media containing 
various concentrations of sodium butyrate and [^ H] thymidine (2.5 uCi/ml), and incubated 
at 37° for 1 hr. Cells were collected and radioactivity in cold trichloracetic acid 
insoluble material was determined as described in the Materials and Methods. The 
concentrations of a- and P-subunits and PAP activity in culture in the absence of 
sodium butyrate were 0.625 Pg/mg protein, 0.054 ng/mg protein, and 0.021 mU/mg protein, 
respectively. Radioactivity incorporated in the absence of sodium butyrate was 618 
cpm/pg protein for [^ H] thymidine. Fold-induction is the ratio of protein levels in 
flasks receiving inducer to the levels in flasks receiving no additions. This defini­
tion was applied in all cases where fold-induction was plotted. 
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for alkaline phosphatase). On the other hand, P-subunit was induced 
only at sodium butyrate concentrations greater than 2 mM and was in­
creased 3.5-fold. At a concentration of 3 mM sodium butyrate, DNA 
synthesis was inhibited by 78%. In the case of a and PAP production, 
their concentration-dependent increase was correlated with the inhibi­
tion of DNA synthesis. As shown in the time course study (Figures 5a 
and 5b), hCG-a and PAP were induced within 3 to 6 hr after the addition 
of 3 mM sodium butyrate, while hCG-g levels increased somewhat later 
(15 hr of incubation). However, it is evident that the rate of induction 
increased markedly about 24 hr after butyrate addition. The inhibition 
of DNA synthesis occurred significantly at early times after butyrate 
addition with 47% inhibition evident after 12 hr of incubation. Thus, 
the inhibition of DNA synthesis occurred prior to the induction of these 
ectopic proteins. The priority of DNA synthesis inhibition for induction 
is consistent with a possible correlation between these events since 
the rate of induction increased immediately after reaching maximal 
inhibition of DNA synthesis (36 hr of incubation). 
Induction of hCG-a, -P, and PAP by DNA Synthesis Inhibitors 
Which Affect Deoxynucleotide Synthesis 
Ghosh et al. (156) suggested that protein induction may be a 
consequence of DNA synthesis inhibition caused by sodium butyrate. 
Moreover, recent findings that well-characterized antineoplastic 
inhibitors of DNA synthesis also stimulated hCG synthesis in HeLa 
cells support the above suggestion. Thus, it may be useful to use 
Figure 5. Kinetics of gonadotropin subunits and alkaline phosphatase 
production in response to sodium butyrate 
Cell cultures and conditions were as described in Figure 4. 
After incubating with or without 3 mM sodium butyrate for 
various times, 2 ml of medium was removed from one flask 
and assayed for a- and P-subunlts (a) or cell extracts 
were prepared from Individual flasks and assayed for PAP 
(b) as described In the Materials and Methods. The amount 
of cell protein was determined. The incorporation of [%] 
thymidine was measured separately in 25 cm^  flasks. Isotope 
(2.5 pCi/ml) was added at the time indicated after sodium 
butyrate addition and labeling was terminated after 1 hr. 
Incorporation of [3H] thymidine into the control culture 
was 720 cpm/mg protein, which was regarded as 0% DNA 
synthesis inhibition. PAP activity in control culture 
was 0.082 mU/mg protein. 
Symbols: rrsubunit production in control cultures (o); 
a-subunit production in butyrate-treated cultures (•); 
p-subunlt production in control cultures (a); P-subunit 
production In butyrate-treated cultures (A); PAP activity 
in control cultures (a); PAP activity in butyrate-treated 
cultures (•); inhibition of DNA synthesis ( ). 
stinoH 
6^  
50 
other Inhibitors of DNÂ synthesis as a tool In the study of the regula­
tion of synthesis of ectopic proteins. 
There are several DNA synthesis inhibitors which alter the 
synthesis of DNA precursors without affecting DNÂ structure. They 
change the amounts of any specific one or all four deoxynucleotides in 
the cells. These include hydroxyurea, 5-fluoro-2'-deoxyuridine, thymidine, 
and methotrexate. Though their mechanism of action on the synthesis of 
DNA precursors are somewhat different from one another, it was of 
interest to determine their effects on the synthesis of of- and P-
subunit and PAP to test the hypothesis that protein induction is re­
lated to the inhibition of DBA synthesis. 
Figure 6 shows protein induction in HeLa Sg cells grown in media 
containing different concentrations of hydroxyurea (HU). The activity 
of alkaline phosphatase was enhanced at lower concentrations of HU 
(0.2 mM) than was that of either subunit. The enzyme was maximally 
Induced 2-fold at 0.5 mM HU and declined in specific activity at 
higher concentrations of this inhibitor (1 mM and 2 mM). On the other 
hand, the production of hCG-a and -p were enhanced gradually up to a 
concentration of 2 mM HU. Maximum induction for alpha and beta were 
2.6- and 1.5-fold, respectively. Although the exact values varied 
somewhat, subsequent experiments demonstrated that the Induced protein 
levels Increased linearly with time up to 72 hr after incubation of 
cultures in media containing 1 mM HU (Figures 7a and 7b). At this 
concentration of hydroxyurea, hCG-a and -p were induced more than 
PAP as expected from the previous experiment (Figure 6). 
The Induction profile of PAP showed a linear increase up to 0.5 mM 
Figure 6. Dose-response curve for induction of hCG-o and - g subunits and PAP, and inhibition of DNA 
synthesis by hydroxyurea in HeLa Sg cell cultures 
Conditions and procedures were as described in Figure 4. The concentrations of a- and g-
subunits and activity of PAP in the control cultures were 0.647 wg/mg protein, 5.1 ng/mg 
protein, and 0.073 mlJ/mg protein, respectively. Radioactivity incorporated into the 
control culture was 618 cpm/pg protein for thymidine. 
Symbols: C»-subunit (•) ; 3-subunit (•) ; PAP (A); DNA synthesis inhibition (- ). 
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Figure 7. Time course of ectopic protein synthesis by hydroxyurea in 
HeLa cells 
a. Kinetics of induction for ot- and p-subunits 
b. Kinetics of induction for PAP 
Conditions and procedures were as described in Figure 5. 
Symbols: or subunit production in control cultures (o); 
a-subunit production in hydroxyurea-treated cultures (•); 
P-subunit production in control cultures (A); p-subunit 
production in hydroxyurea-treated cultures (A); PAP activity 
in control cultures (a); PAP activity in hydroxyurea-treated 
cultures (•); inhibition of DNA synthesis (- ). 
PAP( mil/rag protein I 
M 
a -
\ 
.\ 
W 
8 6 s 8 
( MUllllll % I SISlllllS VNQ 
/I-subunit ( w/mt prttiii I 
5 8 8 
subunit I n/mg pratiii ) 
X 
e 
e 
m 
</» 
( MUllllll XI tisiimsvNO 
55 
hydroxyurea and then decreased at 1 and 2 mM. Increasing concentrations 
of HU caused a gradual increase in a and P production as well as the 
inhibition of DNA synthesis. However, after 3 hr incubation with 
1 mM HU, significant inhibition of DM synthesis (93%) had occurred 
with only minor Induction of the ectopic proteins. Thus, it is possible 
that the inhibition of DM synthesis is required for the induction of 
these proteins in HeLa cells although there is a significant lag 
between inhibition of replication and the maximal rate of induction. 
As shown in Figures 7a and 7b, hCG-a and PAP were induced even at 3 to 
6 hr of incubation, but the concentration of hCG-P was Increased only 
after 15 to 24 hr of incubation. Thus, these data indicate that the 
time-courses for induction of these three proteins in cultures con­
taining 1 mM HU are significantly different from one another, suggesting 
that their mechanism of induction may also be different, though the 
exact processes are not known. 
The induction of or and p-subunit and PAP depends on the concentra­
tion of 5-fluoro-2'-deoxyuridine (FdUrd) as shown in Figure 8. At 
3.8 mM, FdUrd, a 3.7-fold and a 7.2-fold Increase in the production 
of the glycoprotein hormone alpha and beta subunits was observed. 
The activity of PAP was Increased about 1.5-fold at 2.6 |jM FdUrd. At 
higher concentrations of FdUrd (5 PM), the production of all three 
proteins was decreased. DNA synthesis was gradually inhibited up to 
70% by increasing concentrations of FdUrd and did not show any more 
inhibition at 5 pM. Thus, these results suggest that the inhibition 
of DM synthesis and the Induction of ectopic proteins in response 
to FdUrd may be correlated. 
Figure 8. Synthesis of hCG cy-subunit, g-subunit, alkaline phosphatase, and DNA in HeLa cultures 
exposed to 5-fluoro-2'-deoxyuridine 
Conditions and procedures were as described in Figure 4. The concentrations of cr 
and P-subunits in the culture media with no inducer were 0.2 ixg/mg protein and 0.56 
ng/mg protein, respectively. The activity of PAP in control culture was 0.387 mU/mg 
protein. Incorporation of [%] deoxyadenosine into the control culture was 520 cpm/ytg 
protein. 
Symbols: cysubunit (•); P-subunit (A); PAP activity (•); DNA synthesis inhibition ( ). 
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The treatment of HeLa cultures with 4 |iM FdUrd caused an immediate 
increase in the appearance of CK and PAP (after 3 hr of incubation). 
However, the production of p-subunit occurred later (after 15 hr of 
incubation). That is, PAP and hCG-a are produced earlier than hCG-p. 
From the kinetics data (Figures 9a and 9b), it can be seen that, as in 
the case for HU, inhibition of DNA synthesis occurred significantly 
prior to the induction of these proteins since 66% of the DNA synthesis 
inhibition occurred 6 hr after drug addition. DNd synthesis was 
inhibited only 75% even after 72 hr of incubation. 
As shown in Figure 10, thymidine is a poor inducer for hCG-p 
(1.1-fold increase at any dose of thymidine) but a good inducer for 
hCG-of and PAP (2.2-fold and 5.0-fold induction, respectively). More­
over, the optimum concentration (200 ^ M) for PAP induction was dif­
ferent from that for hCG-a production (2 or 3 mM). Data for the higher 
concentrations of thymidine is not shown. About 50% of DNA synthesis 
was inhibited even at low concentrations of thymidine (10 ijM) where cr 
and p-subunit induction was not observed. The inhibition of DNA 
synthesis occurred continuously up to 200 pM thymidine at \diich the 
production of PAP was induced maximally. 
As seen in Figure 11, 100 pM Thd caused a rapid increase in alkaline 
phosphatase activity which continued for 84 hr. Likewise, incorporation 
of [^ H] dAdo was reduced immediately after Thd addition and was in­
hibited maximally (75%) between 12 and 24 hr of incubation. In con­
trast, the levels of orsubunit did not Increase over control values 
until 12 hr after nucleoside addition, but rose steadily thereafter. 
Methotrexate, a folic acid analogue, is another agent which 
Figure 9. Kinetics study of 5-fluoro-2'-deoxyuridine-induced Of- and 
P-subunits, and PAP in HeLa cell cultures 
a. Kinetics of induced a- and P-subunits 
b. Kinetics of induced alkaline phosphatase 
Conditions and procedures were as described in Figure 5. 
Symbols: of-subunit production in control cultures (o); 
a-subunit production in FdUrd-treated cultures (•); P-
subunit production in control cultures (A); p-subunit 
production in FdUrd-treated cultures (A); PAP activity in 
control cultures (a); PAP activity in FdUrd-treated cul­
tures (•) ; inhibition of DNA synthesis ( ). 
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Figure 10. Dose-response curve for the induction of hCG-a, hCG-î3, and PAP by thymidine 
Conditions and procedures were as described in Figure 4. The concentration of hormone 
subunit s in cell cultures receiving no addition of thymidine were 0.752 iJ.g/mg protein 
for a-subunit and 3.39 ng/mg cell protein for p-subunit. Activity of PAP in control 
culture was 0.680 milliunits/mg protein. Incorporation of [^ H] deoxyadenosine was 640 
cpm/kig cell protein in the control culture. 
Symbols: a-subunit (•); 8-subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 11. Time course of hCG subunlts and alkaline phosphatase 
production in thymidine-treated HeLa S3 cell cultures 
a. Kinetics of induced a-subunlt and subunit 
b. Kinetics of Induced alkaline phosphatase 
Conditions and procedures were as described in Figure 5. 
Symbols: crsubunit production in control cultures (o); 
crsubunit production in thymidine-treated cultures (•); 
P-subunit production in control cultures (a); P-subunit 
production in thymidine-treated cultures (A); PAP activity 
in control cultures (a); PAP activity in thymidine-treated 
cultures (•); DNA synthesis inhibition ( ). 
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produces a change in DNA precursor pools, inhibiting dihydrofolate 
reductase and thereby depriving thymidylate synthetase of a necessary 
cofactor. Speeg et al. (173) reported that methotrexate caused an in­
crease in PAP activity in choriocarcinoma cells that became more dose 
related after 4 days incubation but caused an increase in hCG production 
that appeared to be dose related earlier (at 3 days incubation). It 
should be pointed out that the response to this analogue is clearly a 
complex one, involving transport of MTX into the cell, inhibition of 
dihydrofolate reductase, a probable accumulation of unbound MTX, a de­
crease in available thymidine, an inhibition of DNA synthesis, and ulti­
mately, an increase in hCG and PAP specific activity by an unknown 
mechanism(s). Superimposed on this is a possible attempt by the cell 
to synthesize new dihydrofolate reductase and reverse the inhibition of 
DNA synthesis caused by a lack of thymidine (211). In this study, a 
longer incubation time was also required to achieve maximum induction 
of these proteins in HeLa cells with methotrexate. The cultures were 
incubated with different concentration of the drug for 5 days, and then 
media and cell extracts were assayed for a, p, and PAP as in other 
experiments. The optimum concentration for induction of these proteins 
was about 2-4 pM methotrexate, a level which caused 68% inhibition of 
DNA synthesis (Figure 12). Maximum induction of a and PAP were 2.5-
fold and 2.9-fold, respectively. The p-subunit was increased 2-fold at 
a concentration of 4 mM. At 2 |jM methotrexate, induction of hCG-a 
and -p was increased up to 84 hr of incubation (Figure 13a). The 
production of PAP was maximally increased at 72 hr after exposure to 
the drug when DNA synthesis was inhibited 61% (Figure 13b). The 
Figure 12. Concentration curve of ectopic protein Induction by methotrexate In HeLa cells 
Conditions and procedures were as described In Figure 4. The amounts of hormone subunlts 
secreted Into cell culture receiving fresh media without inducer were 0.5 M'g/mg cell 
protein for or-subunit and 3.3 ng/mg protein for 8-subunlt. PAP activity In control 
culture was 0.48 mU/mg protein. Radioactivity incorporated into the control culture 
was 490 cpm/tig protein for thymidine. 
Symbols: a-subunit (•); P-subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 13. Time course of gonadotropin and alkaline phosphatase 
production In HeLa cell cultures exposed to methotrexate 
a. Kinetics of Induced o and P-subunlts 
b. Kinetics of Induced alkaline phosphatase 
Conditions and procedures were as described In Figure 5. 
Symbols: o-subunlt production In control cultures (o); 
o-subunlt production In methotrexate-treated cultures (•); 
8-subunlt production In control cultures (A); p-subunlt 
production In methotrexate-treated cultures (•); PAP 
activity In control cultures (•); PAP activity In 
methotrexate-treated cultures (•) ; Inhibition of DBA 
synthesis ( ). 
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production of PAP (3 hr) and a (12 hr) occurred earlier than that of 
beta subunit (24 hr) after MIX addition. As shown in Figures 13a and 
13b, the inhibition of DNA synthesis was somewhat correlated to 
the induction curves for these proteins. Thus, these data are consistent 
with the possible correlation between the inhibition of DNA synthesis 
and the induction of ectopic proteins in HeLa cells. 
Ara-C acts as a chain terminator in DNA synthesis and blocks the 
entry of cells into the S-phase of the cell cycle as does hydroxyurea. 
In the present study, ara-C was a good inducer in one experiment 
(Figure 14) and not in another (data not shown), though it caused inhibi­
tion of DNA synthesis by 80%. This nonreproducibility may be due to the 
pleiotropic action of ara-C (discussed later). At 1 pg/ml, ara-C caused 
a 1.3-fold increase in a-subunit and a 2.3-fold increase in g-subunit 
in culture media, while a 2.3-fold increase in PAP activity occurred at 
2 [ig/ml ara-C. DNA synthesis was inhibited about 50% at 0.8 tig/ml of 
ara-C (I^ q for DNA synthesis inhibition) (Figure 14). The induction of 
PAP by ara-C (3 hr after incubation) occurred earlier than that of hCG-a 
or hCG-p (12-24 hr after incubation) (Figures 15a and 15b). The 
concentration dependence for induction of ectopic proteins by ara-C 
suggests that DNA synthesis inhibition may play a role in ectopic 
protein induction since DNA synthesis was inhibited by about 80% at 
1.25 ng/ml ara-C and was not inhibited further at higher concentrations 
(over 2 jxg/ml ara-C) at which ectopic protein production declined. 
Moreover, the kinetics of DNA synthesis inhibition are comparable to 
those for the induction of or and p-subunit. That is, DNA synthesis 
was inhibited 60% after exposure to ara-C for 12 hr, and hCG-a and -p 
Figure 14. Ectopic production of gonadotropin subunits and alkaline phosphatase in response to 
arabinofuranosylcytosine 
Conditions and procedures were as described in Figure 4. The concentrations of os- and 
P-subunits and activity of PAP in cell cultures in the absence of ara-C were 0.2 Mg/mg 
protein, 1.84 ng/mg protein, and 0.315 mU/mg protein, respectively. Incorporation of 
[^ H] thymidine into the control culture was 605 cpm/pg protein. 
Symbols: crsubunit (•); P-subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 15. Kinetics of a-subunit, P-subunit, and alkaline phospha­
tase induction by arabinofuranosylcytosine in HeLa Sg 
cell cultures 
a. Kinetics of induced crsubunit and P-subunit 
b. Kinetics of induced alkaline phosphatase 
Conditions and procedures were as described in Figure 5. 
Symbols; o^ subunit production in control cultures (o); 
crsubunit production in ara-C-treated cultures (•); |3-
subunit production in control cultures (A); P-subunit 
production in ara-C-treated cultures (A); PAP activity in 
control cultures (o); PAP activity in ara-C-treated cul­
tures (•) ; inhibition of DN^  synthesis ( ). 
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Increased at about the same time. 
The production of ectopic proteins in HeLa cells was increased 
by the addition of 5-broino-2'-deoxyuridine (Figure 16). Maximum in­
ductions for hCG-a, -p, and PAP were 2.8-, 7.5-, and 2.4-fold, 
q 
respectively, at 20 to 30 pg/ml BrdUrd. About 50% of [ H] deoxyadenosine 
incorporation was inhibited at 10.7 ng/ml BrdUrd DNA synthesis 
inhibition). The inhibition of DNA synthesis occurred at lower concentra­
tions of BrdUrd than those required for p-subunit induction but at 
slightly higher concentrations than those producing increased crsubunit 
and PAP synthesis. Thus, induction of ectopic proteins by BrdUrd did not 
show a close relationship to inhibition of DNA synthesis. Moreover, 
BrdUrd seems not to be a good inducer for a production in HeLa 
cells in certain experiments (data not shown and discussed later). The 
kinetics for induction by BrdUrd was examined and presented in Figures 
17a and 17b. PAP activity increased rapidly after exposing the cells 
to the analogue (20 jjig/ml) and then rose for 72 hr to about 3-4 times 
the baseline level. However, BrdUrd produced only marginal in­
creases in hCG-o and -p synthesis after a 48-hr incubation, even though 
it caused a 70% inhibition of DNA synthesis after only a 6-hr exposure. 
Effects of DNA Polymerase Inhibitors on 
Ectopic Protein Induction 
As described above, most DNA synthesis inhibitors which influence 
replication by altering the metabolism of deoxynucleotides caused the 
induction of ectopic products in HeLa cells. It would be useful to 
Figure 16. Effect of 5-bromo-2'-deoxyuridine on the induction of gonadotropin subunits and alkaline 
phosphatase in HeLa cell cultures 
Conditions and procedures were às described in Figure 4. The hormone subunits, a and P, 
were secreted into culture media not containing BrdUrd in the following amounts: 
0.993 gg/mg protein for or-subunit and 6.7 ng/mg protein for P-subunit. PAP (0.104 
mU/mg protein) was detected in the control culture. Radioactivity incorporated into 
the control culture was 434 cpm/pg protein for [^ H] dAdo. 
Symbols: Of-subunit (•) ; p-subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 17. Kinetics 
response 
of ectopic protein synthesis in HeLa cultures in 
to 5-bromo-2'-deoxyuridine 
a. Time course of hCG subunits induction 
b. Time course of alkaline phosphatase induction 
Conditions and procedures were as described in Figure 5. 
Symbols: crsubunit production in control cultures (o); 
or-subunit production in BrdUrd-treated cultures (•); 
P-subunit production in control cultures (A); p-subunit 
production in BrdUrd-treated cultures (•); PAP activity 
in control cultures (a); PAP activity in BrdUrd-treated 
cultures (•); inhibition of DNA synthesis ( ). 
PAP( mil/mg protein I 
% ) SISJIIHIS VNQ 
fi- subunit ( iig/Bg preteii I 
a-subunit ( MS/ng protein 
z 
e 
c 30 
V> 
8 ft S 8 
(loiiiiiiiix) «saillis VNQ 
80 
determine whether the direct inhibition of DNA synthesis is related to 
the induction of ectopic products. Thus, other types of DM synthesis 
inhibitors which selectively inhibit eukaryotic DNA. polymerase-a 
were examined to test their effect on the induction of ectopic proteins. 
These include aphidicolin and phosphonoformic acid. 
Aphidicolin is a tetracyclic diterpenoid (212) which has been 
shown to inhibit DNA replication of eukaryotic cells and the growth of 
herpes simplex virus, vaccinia virus, and adenovirus (213, 214, 215, 
216, 217, 218, 219). It has been shown to be a specific inhibitor of 
DNA. polymerase-a from several sources (220, 221, 222, 223, 224) but 
not DNA polymerase-p or -y (220, 223, 225) at levels which inhibit 
mitosis. The inhibition by aphidicolin of purified DNA polymerase-a 
from sea urchins, adenovirus-infected KB cells, and HeLa cells is 
competitive with respect to dCTP, while DNA synthesis inhibition in 
isolated nuclei is noncompetitive with respect to all four dNTPs 
(215, 222, 224). 
Aphidicolin increased the production of hCG-a and -p more than 
5-fold at 5-10 pg/ml and induced PAP less than 2.0-fold at 1-2 pg/ml. 
DNA synthesis was inhibited about 90% at a concentration of 0.2 pg/ml 
aphidicolin (Figure 18). The of-subunit was induced even at times as 
early as 3 hr after drug addition (2.5 wg/ml), but there was a lag of 
12 to 24 hr before hCG-8 and alkaline phosphatase activity were increased 
(Figures 19a and 19b). Maximum DNA synthesis inhibition (97%) had 
occurred at the earliest time examined (3 hr). The dose-response and 
time-course data did not show an exact correlation between the in­
duction of ectopic proteins and DNA synthesis inhibition, though 
Figure 18. Synthesis of hCG subunits and alkaline phosphatase in aphidicolin-treated HeLa cell 
cultures 
Conditions and procedures were as described in Figure 4. The amounts of hormone sub-
units in control cultures with no addition of aphidicolin were 2.07 Mg/mg protein for 
Qf-subunlt and 10.84 ng/mg protein for B-subunit. The activity of PAP in control cul­
ture was 2.02 mU/mg protein. [^ H] thymidine (736 cpm/vig protein) was incorporated into 
control cell culture. 
Symbols: crsubunit (•); subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 19. Time course for the synthesis of aphidicolin-induced hCG 
subunits and alkaline phosphatase in HeLa cultures 
a. Kinetics of hCG subunits induction 
b. Kinetics of PAP induction 
Conditions and procedures were as described in Figure 5. 
The activity of PAP in control culture was 0.401 mU/mg pro­
tein. 
Symbols: ty-subunit production in control cultures (o) ; 
(y-subunit production in aphidicolin-treated cultures (•); 
P-subunit production in control cultures (A); g-subunit 
production in aphidicolin-treated cultures (A); PAP activity 
in control cultures (o); PAP activity in aphidicolin-treated 
cultures (•); inhibition of DNA synthesis ( ). 
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significant inhibition of DNA synthesis occurred prior to the induction 
of these proteins. 
Trisodium phosphonoformate selectively inhibits cell-free DNA 
polymerase activity induced by herpes virus (226). It also inhibits the 
DNA polymerase-a activity from mammalian cells (227). Phosphonoformic 
acid had no effect on RNA and protein synthesis at a concentration of 
up to 2.5 mM, and 100 ijM phos phono formic acid did not influence HeLa 
cell proliferation (228). 
Phosphonoformic acid caused an increase in the production of PAP, 
hCG-a and (Figure 20). A 7.7-fold Increase in PAP activity was 
produced by 3.1 mM PFA, and a 2.3-fold increase in subunit and a 
3.2-fold increase in p-subunit were produced by about 2 mM PFA. The 
FI^ q value (0.68 mM PFA) for PAP induction was about half of that for 
Of or p induction (1.4 or 1.3 mM PFA). DNA synthesis was inhibited 
about 50% by 0.22 mM PFA at which there was no significant induction 
of these proteins. Each of the ectopic products increased within 3 hr 
after exposure to the drug (Figures 21a and 21b), and over 90% of DNA 
synthesis was inhibited by exposure of cells for 3 hr to 2.5 mM PFA. 
Maximal induction occurred at 12 to 18 hr of incubation with PFA and 
declined after 24 hr exposure to the drug. Thus, experiments were 
generally terminated 20 hr after PFA addition. 
Though there was some variability, aphidicolin was in general a 
better inducer of the hormone subunits than alkaline phosphatase, while 
PFA was generally a better inducer of PAP than either the cr or p-
subunits. Since inhibition of DNA synthesis occurred prior to induction 
of ectopic proteins with both PFA and aphidicolin, the possibility of a 
Figure 20. Effect of phosphonoformic acid on the induction of Of-subunit, p-subunit, and alkaline 
phosphatase in HeLa cell cultures 
Conditions and procedures were as described in Figure 4. The concentrations of ectopic 
proteins in control cultures were 0.54 ng of-subunit/mg protein, 9.44 ng g-subunit/mg 
protein, and 9.26 mU PAP/mg cell protein. Incorporation of [^ H] thymidine was 849 cpm/ 
pg cell protein into the control culture. 
Symbols; crsubunit (•); P-subunit (A); PAP (•); DNA synthesis inhibition ( ). 
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Figure 21. Kinetics of human chorionic gonadotropin subunlts and 
alkaline phosphatase production In HeLa cultures exposed to 
phosphonoformlc acid 
a. Kinetics of hCG subunlts Induction 
b. Kinetics of PAP Induction 
Conditions and procedures were as described In Figure 5. 
PAP activity In control cultures was 0.12 mU/mg pro­
tein. 
Symbols: cy-subunlt production In control cultures (o); 
ry-subunlt production in PFA-treated cultures (•); p-
subunlt production in control cultures (A); g-subunit 
production In PFA-treated cultures (•); PAP activity in 
control cultures (a); PAP activity in PFA-treated cultures 
(•); inhibition of DNA synthesis ( ). 
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direct relationship between DNA synthesis Inhibition and ectopic protein 
Induction cannot be ruled out. However, protein Induction required 2-10 
times more drug than was necessary to inhibit DNA replication. This 
result suggests the possibility that some factor(s) other than DNA. 
synthesis inhibition may be involved in protein induction or that this 
drug may act indirectly to cause the induction of these proteins. 
Classification of Inducers 
To conq>are the degree of induction for hCG-oe and -p by several 
DNA synthesis inhibitors, an experiment was carried out in which the 
induction of subunlts was measured in response to several Inducers at 
the same time. Replicate cultures received those concentrations of 
inhibitor previously determined to produce maximum Induction. As shown 
in Figures 22a and 22b, the DNA synthesis inhibitors can be classified 
into three groups designated as high inducers (sodium butyrate), inter­
mediate Inducers (FdUrd, HI), and ara-C), and low Inducers (Brdllrd) 
depending on the degree of Induction of the hCG subunlts. To compare 
the action of these three classes of Inducers, combination studies have 
been carried out (Tables VIl-IX) and will be described below. 
Induction of hC6-a, -g, and PAP by DNA Synthesis 
Inhibitors Which Alter DNA Structure 
Among the inhibitors of DNA synthesis, many of them cause strand 
scission and chromosome rearrangements or Intercalate in or otherwise 
bind to the DNA helix. To test the effect of these kinds of inhibitors 
Figure 22. Time course of hCG-a and -p induction in HeLa S3 cell 
cultures by several DNA synthesis inhibitors 
Cells were grown in a medium with or without each of several 
DNA synthesis inhibitors and induced a- or P-subunits 
were assayed. Conditions and procedures were as described 
in Figures 4 and 5. 
Symbols ; control (o) ; 3 mM Btr (•) ; 1 mM HU (•) ; 4 jaM 
FdUrd (A); 1.25 M-g/ml ara-C (•) ; 20 |Jg/ml BrdUrd (a). 
The concentrations of inducers were those previously 
determined to produce maximum induction. 
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on the Induction of ectopic products in HeLa cells, several anti­
biotics and anti-tumor drugs have been examined. These include ethidium 
bromide, acridine, mitomycin C, bleomycin, macromomycin, and cesalin. 
Ethidium bromide intercalates between base pairs and induces an 
unwinding of the DNA double helix (229). It acts also as an inhibitor 
of DM synthesis as well as an inhibitor of RNA synthesis (230, 231). 
Another intercalating agent, acridine, has been widely used as a photo-
dynamic mutagen (232). 
The antibiotic mitomycin C is an inhibitor of DNA biosynthesis 
(233) and is linked to DNA by intermolecular forces. On chemical or 
enzymatic reduction in the presence of DNA, it reacts covalently with 
DNA, forming cross links in some cases (234). This prevents the separa­
tion of the complementary DNA strands. Hence, mitomycin C is primarily 
an inhibitor of DNA replication and inhibits the growth of several 
tumors (235). 
Bleomycin is a peptide which reacts with DNA and causes strand 
scission. It is more effective in combination with quinone-containing 
anticancer agents such as mitomycin C, daunomycin, and reducing vitamins. 
At low concentrations, it causes elimination of bases, particularly 
thymine. Thus, it causes strand breakage of DNA, chromosomal 
aberrations, and inhibition of synthesis of specific proteins. It 
inhibits growth of HeLa cells in culture. It also inhibits 
DNA ligase (236, 237). 
Macromomycin is a protein isolated from the culture filtrate of 
Streptomvces macromvceticus. It is an antibiotic and also cytotoxic 
to a broad spectrum of carcinoma cells. The cytotoxicity results in 
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inhibition of DNA, RNA, and protein synthesis (238). This antitumor 
protein inhibited HeLa cell growth at nanomolar concentrations. 
Incubation of macromomycin with HeLa cells resulted in a rapid 
fragmentation of cellular DNA (239, 240). It produces strand scission 
of DNA in KB cells, which might appear to correlate with its concomitant 
inhibition of thymidine and uridine incorporation into nucleic acids. 
Cesalin, another antitumor protein, which does not possess DNA 
cleavage activity can inhibit DNA synthesis and mitotic division 
independently of one another. The ability of cesalin to inhibit DNA 
synthesis and mitosis does not appear to be phase-specific. The exact 
mechanism of the inhibition of DNA synthesis is yet undetermined (241, 
242). 
Thus, the agents described above share the common property of pro­
ducing chromosomal aberrations either by binding, intercalation, strand 
cleavage, or the like. They do not induce alkaline phosphatase or the 
gonadotropin subunits in HeLa cells over a several-fold range in 
concentration (Table II). Rather, they inhibited the production of 
these proteins at their basal level even though they markedly inhibited 
the synthesis of DNA in these cells. Kinetic experiments showed no 
significant difference in the levels of these proteins between nonex-
posed and exposed cells after 72 hr of incubation with drugs at a 
concentration which produced 40 to 60% DNA synthesis inhibition. 
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Table II. Effects of DNA synthesis inhibitors which alter DNA. struc­
ture on the induction of ectopic proteins^  in HeLa cells 
Induction 
fold DNA synthesis 
Inhibitors Concentration a P PAP inhibition (%) 
Mitomycin C 0 loM 1.0 1.0 1.0 0 
1.25 0.9 1.0 0.6 48 
5 0.9 0.9 0.5 91 
10 0.9 0.8 0.6 96 
Ethidium 0 (jg/ml 1.0 — 1.0 0 
bromide 2.5 1.0 — 0.8 25 
7.5 0.5 — 0.7 89 
15 0.4 -— 0.6 91 
Cesalin^  0 ng/ml 1.0 — 1.0 0 
0.2 0.8 — 0.7 8 
1.0 0.5 — 0.3 60 
3.0 0.4 '— 0.2 91 
Acridine 0 jiM 1.0 — 1.0 0 
5 1.1 — 1.0 21 
20 1.5 — 0.8 20 
100 1.4 — 0.5 44 
400 1.2 — — 90 
Bleomycin^  0 3 units/ml x 10 1.0 — 1.0 0 
1.5 1.4 — 1.1 8 
7.5 1.1 — 0.8 16 
15 1.1 — 0.6 31 
30 1.2 — 0.5 69 
Macromomycin^  0 tig/ml 1.0 — 1.0 0 
2.5 1.1 — 0.6 4 
5 0.8 — 0.5 14 
10 1.2 — 0.5 27 
20 0.9 — 0.3 63 
40 0.5 — 0.2 83 
p^-subunit production was not detected in cultures exposed to most, 
if not all inhibitors. 
'^ Cesalin is an oligomeric protein of molecular weight around 
110,000. 
S^tructures of Bleo and Mcr are shown in Figure 26. 
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Table II. Continued 
Conditions and procedures were as described in Figure 4. 
Experiments were performed over a several-fold range of Inhibitor 
concentration. Qf-Subunit production in control cultures was 0.486 
Hg/mg protein and PAP activity in control cultures was 3.31 milllunlts/ 
mg cell protein. Incorporation of [3H] thymidine into cell cultures 
in the absence of Inhibitor was 513 cpm/pg protein. 
Fold induction is the ratio of protein levels in flasks receiving 
drug to the levels in flasks receiving no additions. 
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Effect of DNA Synthesis Inhibitors on 
Macromolecular Synthesis 
The lack of Induction by the DNA synthesis inhibitors which alter 
DM structure might result if these compounds also inhibit RM and 
protein synthesis after a prolonged exposure to these drugs. This 
3 
assumption can be tested by monitoring the incorporation of [ H] 
3 3 thymidine, [ H] uridine, or [ H] leucine to determine the effect of 
these drugs on the rate of macromolecular synthesis. 
As shown in Table III, the group of compounds which influences 
the metabolism of DM synthetic precursors inhibited DM synthesis 
more specifically than RM or protein synthesis. That is, the inhibi­
tion of RM (0 to 25%) or protein synthesis (0 to 40%) by these inhibitors 
was considerably less than that of DM synthesis (50 to 99%). On the 
other hand, the group of inhibitors which alters DM structure pro-
3 duced a significant decrease in the incorporation of [ H] uridine and 
[%] leucine as well as [^ H] thymidine into acid-insoluble material. 
These compounds inhibited macromolecular synthesis 50 to 99% at the 
concentration of each compound used for induction experiments. Thus, 
these data suggest that the induction of ectopic products requires RM 
and protein synthesis. This suggestion was confirmed with a subsequent 
experiment in which more specific inhibitors of RM or protein synthesis 
were examined to determine their effects on the induction of these 
proteins in HeLa S^  cells (see below). 
/ 
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Table III. Effect of DNA synthesis inhibitors on the synthesis of 
macromolecules in HeLa cells 
Hacromolecular synthesis 
(7c inhibition) 
Compounds Concentration DNA RNA. Protein 
Btr 3 mM 71 0 27 
5 mM 68 0 23 
HU 1 mM 17 0 0 
2 mM 70 0 33 
FdUrd* 3 yM 17 9 19 
10 WM 67 26 33 
Thd® 50 iJiM 44 3 0 
100 pM 77 34 45 
MTX 2 (JM 84 0 0 
20 IJM 91 0 16 
Ara-C 3 (Jg/ml 92 0 0 
5 pg/ml 89 0 0 
BrdUrd^  125 ixg/ml 18 15 2 
250 Jig/ml 53 21 42 
500 M-g/ml 78 61 71 
Aph 1 Mg/ml 93 11 22 
2.5 Pg/ml 97 17 31 
5.0 (Jg/ml 99 27 31 
PFA 1.25 mM 82 14 28 
3.75 mM 91 55 62 
Mitomycin C 10 pM 30 48 68 
25 ViM 62 59 79 
Bleomycin 15 mU/ml 98 65 68 
Ethidium 10 (xg/ml 98 88 79 
bromide 20 (Jg/ml 99 93 83 
a 3 [ H] deoxyadenosine was used for labeling cells to measure the 
rate of DNA synthesis. 
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Table III. Continued 
Macromolecular synthesis 
(% Inhibition) 
Compounds Concentration DM RKÂ Protein 
Acridine 50 pM 86 76 67 
100 tiM 87 78 78 
Cesalin 2 ng/ml 76 58 58 
4 ng/ml 94 72 53 
Macromomycin 4 Mg/ml 38 62 52 
10 IJg/ml 48 63 60 
Cells were grown to confluence In 24-well cluster plates at which 
time the media were replaced with fresh RPMI-1640 containing no further 
additions or the compounds as indicated. After 24 hr, cells were 
labeled for 1 hr at 37° with either [%] thymidine (2,5 |JjCi/ml), 
[%] deoxyadenosine (5 jiCi/ml), [^ H] uridine (2.5 nd/rnl), or [^ H] 
leucine (2.5 pCi/ml) together with several concentrations of each com­
pound. Radioactivity was determined as indicated in the Materials and 
Methods. Numbers represent the percent inhibition of DNA, RNA, or 
protein synthesis where flasks receiving no inhibitor were set at 
100%. The concentrations of inducers used here were those near the 
optimum concentrations for induction of ectopic products and the 
concentrations of noninducers were those near I50 for DNA synthesis 
inhibition. Levels of incorporation (cpm/jxg cell protein) of the 
various isotopes in absence of inhibitors were 588, 531, 76, and 66 
for [%] Thd, [%] dAdo, [^ H] Urd, and [^ H] L-leu, respectively. 
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Requirement for RNA and Protein Synthesis for the 
Induction of Ectopic Proteins 
To confirm the hypothesis that RNA and protein synthesis are re­
quired for the induction of ectopic proteins in HeLa cells, the 
effect of actinomycin D aW cycloheximide on the induction of hCG-a 
by sodium butyrate, phosphonoformic acid, and aphidicolin has been 
examined. RNA, or protein synthesis inhibitors were added 24 hr 
after inducer addition. As shown in Figures 23a, b, and c, induction 
of hCG-a was inhibited to basal levels by 0.25 |Jg/ml actinomycin D (over 
90% RNA, synthesis inhibition) or 50 mM cycloheximide (about 75% protein 
synthesis inhibition). The accumulation of crsubunit in response to 
Btr, Aph, and PFA ceased almost completely upon the addition of 50 pM 
cycloheximide, but when actinomycin D was added at 0.25 pg/ml, the 
production of the hormone subunit was inhibited significantly only after 
a 24-hr delay. Such a result would be consistent with a continued 
translation of existing crmRNA during this period. Thus, the induction 
of a-subunit by these agents appears to require continued transcription 
and translation. 
Characterization of Induced crSubunit and Alkaline Phosphatase 
It was of interest to determine whether cf-subunits synthesized in 
response to the various inducers were similar to the uninduced or 
the placental subunit (authentic a) and whether induced alkaline 
phosphatases were of the placental type. 
Figure 23. Effect of actinomycin D and cycloheximide on hCG-Of subunit induction by sodium butyrate, 
aphidicolin, and phosphonoformic acid 
When cells were confluent, cultures were replaced with fresh media containing no inducer 
or 3 mM sodium butyrate (A), 2.5 M-g/ml aphidicolin (B), or 2.5 mM phosphonoformic acid 
(C). After incubating for 24 hr at 37°, 0.025 ng/ml of actinomycin D or 2 x 10~5 M 
cycloheximide were added to cell cultures exposed to these inducers and cultures were 
incubated further. At the time indicated, medium from each flask-was taken out and as­
sayed for Of-subunit in RIA as described in the Materials and Methods. 
Symbols: control culture (©); butyrate-treated culture (•) ; Btr + Act D (o) ; Btr + CHX 
(®); aphidicolin-treated culture (A); Aph + Act D (A); Aph + CHX (A); phosphonoformic 
acid-treated culture (•); PFA + Act D (•); PFA + CHX (B). 
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Dose response curve of induced or-subunits 
It has been reported that serial dilutions of HeLa tissue culture 
medium paralleled standard curve dilutions of hCG-a in the crsubunit 
radioimmunoassay, indicating immunological identity, although HeLa-a 
had a slightly higher apparent molecular weight as determined by gel 
filtration (27). Thus, dose-response curves were established to compare 
the immunological similarity of induced subunits to the noninduced HeLa 
protein and authentic urinary hCG-a. The results for Btr, Aph and PFA 
are presented in Figure 24. The slopes of dose-response curves for the 
media from cultures supplemented with inducers were indistinguishable 
from that for the HeLa subunit in media from uninduced cultures as well 
as authentic hCG-a. Media from cultures incubated with several other 
inducers were examined in a similar manner and the results are presented 
in Table IV. Linear regression analysis of these curves allows compari­
son of their slopes and consequently an estimate of their immunologic 
similarity. The slopes of dose-response curves of urinary and uninduced 
orsubunit were -0.489 and -0.548, respectively. As shown in Table IV, 
most cysubunits produced in response to DNA synthesis inhibitors gave 
slopes ranging from -0.453 to -0.543. Thus, it was concluded that 
there is no significant difference in antibody recognition of urinary, 
noninduced, and induced a-subunits. These data suggest that the cr 
subunits synthesized by HeLa cells in the presence of several in­
ducers have immunologic determinants similar to those of authentic 
urinary hCG-a, and that it is the free subunit which increases in 
response to the drugs and not holo hCG, which gives a slope of -0.275 
in the a RIA. 
Figure 24. RIA dose-response curves for HeLa uninduced and induced cv-subunits 
Increasing volumes of media from uninduced HeLa cultures (•), or cultures treated with 
3 mM butyrate (A), 2.5 jJig/ml aphidicolin (•), or 2.5 mM phosphonoformic acid (•) were 
assayed in the standard Of-subunit RIA. Urinary hCG-a (o) was run for comparison. 
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Table IV. Linear regression analysis of dose-response curves for 
o-subunits induced by DNA synthesis inhibitors® 
Inducer Slope 
None -0.548 
HU -0.543 
FdUrd -0.521 
Thd -0.453 
MTX -0.504 
Ara-C -0.535 
BrdUrd -0.467 
Conditions and procedures were as described in Figure 24 and in 
the Materials and Methods. The slope for each curve was determined 
by using calculator program for linear regression analysis. 
T^he slope for urinary hCG-a was -0.489 in this assay. 
107 
Characterization of induced alkaline phosphatases 
To characterize the alkaline phosphatases induced by various agents, 
thermostability and inhibition studies were carried out on enzymes 
partially purified by butanol extraction as previously described (233). 
Placental alkaline phosphatase may be heated at 65° for up to 60 min 
with no significant loss of activity (153). Under these conditions, 
liver, bone, kidney, and intestinal alkaline phosphatases are rapidly 
destroyed. Extracts were heated at 56° for 30 min and then assayed as 
described in the Materials and Methods section. As shown in Table V, 
all of the induced alkaline phosphatases as well as control enzyme 
were heat-stable. Thus, this heat-stability suggests the induced alka­
line phosphatase as well as the basal enzyme in UeLa S3 cells are of the 
placental form. 
Several lines of evidence suggest that at least three separate 
structural loci are involved in determining the protein portion of the 
different AP enzymes: one coding for the placental enzyme, a second 
for the intestinal enzyme, and at least one locus for the bone, liver, 
and kidney forms of the enzyme. Quantitative inhibition studies with 
L-phenylalanine (L-phe), L-homoarginine (L-Har), L-leucine (L-leu), 
and L-phenylalanylglycylglycine (L-PGG) give identical inhibition 
profiles with the liver, bone, and kidney enzymes but sharply distinguish 
this group of enzymes from the placental and intestinal enzymes, which 
are also sharply distinguished from each other. For placental AP, 
there is marked inhibition with L-phe and L-PGG, modest inhibition with 
L-leu, and only slight inhibition with L-Har and EDTA. The intestinal 
enzyme shows an inhibition profile similar to that obtained for the 
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Table V. Heat stability of alkaline phosphatases induced by DNA 
synthesis inhibitors® 
Activity 
Inducer remaining (%) 
None 107 
Btr 107 
Aph 104 
PFA 104 
HU 111 
FdUrd 109 
Thd 101 
Ara-C 109 
BrdUrd 101 
Alkaline phosphatases were extracted and purified by the method 
of Bussman et al. (209). Samples were heated at 56°C for 30 min and 
then immediately transferred to an ice bath in which unheated samples 
were maintained for the same times. Specific activities (milliunits/ 
mg cell protein) of the various preparations were: control, 8.2; 
Btr, 65; HU, 18; FdUrd, 40; Thd, 315; ara-C, 43; BrdUrd, 32; Aph, 
265; PFA, 714; PAP, 6370. In each assay, approximately 0.25 milli­
units of enzyme was added to each tube. The activity of alkaline 
phosphatase was assayed as described in the Materials and Methods. 
Absorbance values were compared to those for samples left on ice 
during the preincubation at elevated temperatures, which were regarded 
as 100%. 
T^he remaining activity of term placental alkaline phosphatase 
was 106 percent by heating at 60° for 30 min. 
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placental enzyme except inhibition of intestinal AP with L-PGG is very 
slight. On the other hand, the inhibition profile of liver, bone, and 
kidney enzymes is clearly distinct from that obtained from placental or 
intestinal enzymes. That is, there is a marked inhibition with L-Har, 
modest inhibition with L-leu, and only slight or no inhibition with 
L-phe and L-PGG. 
Figure 25 (a-d) and Table VI show the inhibition profiles obtained 
for alkaline phosphatases induced by DNA, synthesis inhibitors, basal 
HeLa enzyme, and authentic placental alkaline phosphatase. At 10 mM 
homoarginine, induced alkaline phosphatases were inhibited 10 to 25% 
while uninduced and authentic alkaline phosphatase were inhibited 20 to 
30%. Addition of leucine caused 40 to 60% inhibition of activity of 
all enzymes. L-PGG (10 mM) and L-phe (10 mM) caused 55 to 65% and 60 
to 70% inhibition of activity of all enzymes, respectively. Each of the 
alkaline phosphatase activities was inhibited 5 to 10% by addition of 
10 mM EDTA. Thus, the inhibition in the presence of each of the in­
hibitors was essentially the same for all induced alkaline phosphatases 
as well as for control HeLa alkaline phosphatase and placental alkaline 
phosphatase, although there were slight variations among them. Induced 
alkaline phosphatases were inhibited greatly by L-phenylalanyIglycyl-
glycine and L-phenylalanine (55-70%), moderately by L-leu (40-60%) 
and only slightly by L-homoarginine (10-25%) and EDTA (5-12%). Thus, 
the induced alkaline phosphatases are characteristic of the term pla­
cental form, which is heat-stable, sensitive to L-PGG and L-phe and 
resistant to L-Har and EDTA. 
Figure 25. Effect of various agents on the activity of Induced and un-
Induced alkaline phosphatases 
Inhibition studies were carried out as described previously 
(62). Reaction mixtures contained 0.33 ml of 24 mM p-
nitrophenylphosphate as substrate and the concentrations of 
L-Homoarglnlne (A), L-Leuclne (B), L-Phenylalanylglycylgly-
cine (C), and L-Phenylalanine (D) as indicated in the 
figure. Results are expressed as the percent of enzyme 
activity in the presence of the particular inhibitor com­
pared to that in the absence of inhibitor which was regarded 
as 100%. Specific activities (mllliunlts/mg protein) of 
the various preparations were as described in Table V. 
In each assay, approximately 0.25 mllliunits of enzyme was 
added to each tube. 
Symbols: placental alkaline phosphatase (o); uninduced 
alkaline phosphatase (o); butyrate-induced alkaline phospha­
tase (•); Aph-induced alkaline phosphatase (A); PFA-lnduced 
alkaline phosphatase (•). 
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Table VI. Inhibition of alkaline phosphatases Induced by several 
Intermediate Inducers with L-amino acids and EDTÀ 
Source of Alkaline phosphatase activity (% inhibition) 
alkaline Har (mM) Leu (mM) 
phosphatase 2.5 5 10 15 25 0.5 1. 25 2.5 5 10 
Placental 9 24 33 39 — 0 4 7 22 43 
HeLa 
unlnduced 0 6 — 20 32 0 7 14 28 52 
HU Induced 4 6 14 25 36 0 0 16 28 65 
FdUrd Induced 4 7 15 23 38 1 4 5 28 55 
Thd induced 0 6 16 18 34 0 1 16 33 58 
Ara-C induced 0 0 12 17 35 0 6 7 28 58 
BrdUrd induced 0 8 12 23 36 3 4 8 25 53 
Conditions and procedures were as described in Figure 25 and In 
the Materials and Methods. The Inhibition results are expressed as 
percent activity inhibited in the presence of particular inhibitor. 
Specific activity of each enzyme preparation and number of units as­
sayed were the same as those described in Table V. 
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Alkaline phosphatase activity (% inhibition) 
Pheglvelv (mM) Phe (mM) EDTA (mM) 
0.25 0.5 1.25 2.5 10 0.625 1. 25 2.5 7.5 20 2.5 5 10 25 50 
5 7 11 22 63 4 11 21 51 100 33 41 45 49 50 
0 0 1 4 59 0 7 13 44 99 0 3 4 6 14 
0 0 6 14 62 0 0 10 38 99 0 16 17 32 16 
3 4 7 15 55 7 8 16 41 99 0 8 9 9 15 
0 3 3 12 55 0 3 7 39 99 0 0 0 12 15 
0 0 0 6 49 0 0 4 35 99 0 0 0 3 7 
0 0 4 4 28 0 5 15 50 99 0 0 5 13 13 
114 
Combined Effects of Sodium Butyrate, Intermediate-, 
Low-, and Noninducers 
If sodium butyrate and the various inhibitors of DNA synthesis act 
through different mechanisms to increase ectopic proteins, the increase 
of production in the presence of both types of inducers should be 
greater than the increase in the presence of each type alone. However, 
such additivity should not be observed if both types of inhibitors act 
through the same or similar mechanisms. It was of interest to compare 
high-, intermediate-, and low-inducers (Figure 22) to determine whether 
they cause induction via similar or different mechanisms in HeLa 
cell cultures. Thus, combination experiments were performed to examine 
the relationship among the three different classes of Inducers. 
HeLa cells were grown for 72 hr in the standard medium con­
taining each of the inducers alone or in the pairs indicated in Tables 
VII, VIII, and IX, where the doses of each inhibitor were known to be 
optimal for induction. The cells and media were harvested and assayed 
for the ectopic proteins. Simultaneous addition of a DNA synthesis 
Inhibitor and sodium butyrate generally gave values which exceeded the 
sum of the levels produced in response to each inducer alone (Table VII). 
The effects of sodium butyrate in combination with intermediate inducers 
were truly synergistic, suggesting that their modes of action are not 
the same. Such additivity was not observed when two Intermediate in­
ducers were added together (Table IX). Rather, the various combinations 
of intermediate inducers generally gave less ectopic protein induction 
than did each inducer alone. This would suggest that the modes of 
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Table VII. Combined effect of sodium butyrate and intermediate in­
ducers on ectopic protein induction in HeLa S3 cells 
Fold induction Combined 
Compounds a P PAP effect* 
None 1.0 1.0 1.0 — 
Btr 9.0 20.6 4.4 — 
HU 3.1 49.4 3.8 — 
Btr 
HU 
13.1 167.9 21.6 S 
FdUrd 2.1 1.8 2.1 — 
Btr 
FdUrd 19.3 27.9 6.7 S 
Thd 1.9 1.4 3.9 — 
Btr 
Thd 15.6 22.0 9.6 s 
MTX 2.0 1.9 1.5 — 
Btr 
MTX 13.8 22.8 6.2 s 
Ara-C 2.1 4.0 1.7 — 
Btr 
Ara-C 11.1 30.1 7.9 s 
BrdUrd 1.4 1.4 1.5 — 
Btr 
BrdUrd 8.4 18.1 4.5 I 
Aph 8.7 15.8 4.2 — 
S, synergism — combined effect was greater than the sum of 
either inducer alone. I, inhibition — combined effect was less than 
the sum of either inducer alone. 
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Table VII. Continued 
Fold induction Combined 
Compounds a P PAP effect 
214.2 20.9 S 
18.1 4.2 
84.4 23.5 S 
2 Cells in 75 cm monolayer flasks were treated with one inducer 
alone or with each intermediate inducer together with sodium butyrate 
and incubated for 3 days. Alkaline phosphatase and a- and p-subunits 
were assayed as described in the Materials and Methods. The 
concentrations of compounds previously determined to be optimal for 
induction were 3 mM Btr, 1 mM HU, 4 pM FdUrd, 100 pM Thd, 2 [jM MTX, 
1.25 (Ag/ml Ara-C, 20 |Jg/ml BrdUrd, 2.5 pg/ml Aph, and 2.5 mM PFA. 
Values in the absence of inducers were 0.65 p-g/mg protein for a-
subunit, 5.1 ng/mg protein for P-subunit, and 0.387 mU/mg protein 
for PAP. 
Btr 
Aph 
PFA 
Btr 
PFA 
21.1 
7.0 
18.4 
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Table VIII. Combined effect of sodium butyrate and noninducers on 
ectopic protein induction in HeLa S3 cells 
Fold induction Combined 
Compounds a P PAP effect® 
None 1.0 1.0 1.0 — 
Btr 9,4 25.8 5.8 -
Mit C 0.7 1.1 1.2 — 
Btr 
Mit C 8.4 23.5 5.4 I 
Bleo 1.2 N.D.b 0.7 — 
Btr 
Bleo 9.4 15.6 3.1 I 
EB 0.7 N.D.b 1.3 — 
Btr 
EB 4.4 2.0 4.1 I 
Acr 1.8 0.6 0.8 — 
Btr 
Acr 8.2 6.8 2.9 I 
Ces 0.7 0.5 0.6 — 
Btr 
Ces 8.6 13.7 4.8 I 
Mer 0.9 N.D.^  1.0 -
Btr 
Mer 10.1 13.4 4.5 I 
*1, inhibition — combined effect was less than the sum of 
either c ompound alone. 
D., not detected. 
Table VIII. Continued 
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Conditions and procedures were as described in Table VII and 
in the Materials and Methods. The concentrations of the compounds 
which did not induce )%re known to cause 50% inhibition of DNÀ 
synthesis, that is, 30 pM Mit C, 10 milliunits/ml Bleo, 4 pg/ml 
EB, 75 |J.M Acr, 1.0 ng/ml Ces, and 15 pg/ml Mcr. 
Control values are the same as in Table VII. 
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Table IX. Effect of combining various intermediate inducers on 
ectopic protein induction in HeLa cells 
Fold induction Combined 
Compounds Of P PAP effe 
None 1.0 1.0 1.0 — 
HU 2.4 2.7 4.7 -
FdUrd 2.8 5.7 3.1 — 
Thd 1.9 1.5 11.5 — 
Ara-C 2.1 3.2 2.3 — 
Aph 6.7 5.6 5.2 — 
PFA 5.3 6.4 5.2 — 
HU 
FdUrd 2.5 N.D.^  3.6 I 
HU 
Thd 3.8 3.8 4.4 I 
HU 
Ara-C 3.3 4.1 4.2 I 
HU 
Aph 3.9 6.6 7.1 I 
HU 
PFA 
2.6 3.4 3.5 I 
FdUrd 
Thd 1.7 1.8 3.1 I 
FdUrd 
Ara-C 2.6 3.4 3.5 I 
Thd 
Ara-C 1.8 
N.D.b 2.8 I 
I^, inhibition — combined 
either inducer alone. 
effect was less than the sum of 
N^.D., not detected. 
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Table IX, Continued 
Conditions and procedures were as described in Table VII. 
The concentrations of intermediate inducers previously determined 
to be optimal for induction were 1 mM HU, 4 |iM FdUrd, 100 ijM Thd, 
1.25 ng/ml ara-C, 2.5 ng/ml Aph, and 2.5 mM PFA. 
Control values are the same as in Table VII. 
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action of these DNA synthesis Inhibitors are similar. The nonlnducers 
such as mitomycin C, bleomycin, etc. (from Table II) did not Increase 
Induction by sodium butyrate. The decrease In ectopic production upon 
prolonged treatment of cultures with these compounds was probably due 
to their Inhibitory effects on general macromolecular synthesis as 
described above. 
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DISCUSSION 
Introductory Remarks 
The use of simple chemical compounds that modulate the synthesis 
of proteins or polypeptides by cells provides a system for investigating 
the regulation of gene expression. Ectopic proteins in HeLa cells 
can be induced by several DNA synthesis inhibitors. 
The present study has shown that a variety of compounds which 
inhibit DNA synthesis lead to the increased production of placental 
alkaline phosphatase and the glycoprotein hormone subunits in HeLa 
cells. The suggested mechanisms of action of inducers described below 
and their effects on induction are summarized in Table X. In general, 
compounds which alter deoxynucleotide metabolism were good inducers of 
these ectopic proteins while agents which alter DNA structure by inter­
calation or covalent binding were poor inducers. 
One of the best inducers for PAP and a-subunit was sodium 
butyrate, which has been reported to enhance ectopic synthesis of 
placental proteins, including the placental isoenzyme of alkaline 
phosphatase as well as the hormone hCG-of and -p subunits in HeLa 
cells (110, 243). The mechanism by which sodium butyrate enhances 
hCG and PAP synthesis in HeLa cells is not known, though Ghosh et al. 
(156) suggest that protein induction may be a consequence of DNA 
synthesis inhibition caused by this agent. Moreover, the findings 
that two well-characterized anti-neoplastic inhibitors of DNA synthesis, 
hydroxyurea and ara-C (92, 111) also stimulated hCG synthesis in 
HeLa^ g cells suggest that the inhibition of DNA synthesis or cell 
Table X. Summary of DNA synthesis inhibitors and suggested mechanisms of action 
DNA synthesis 
inhibitor 
Suggested mechanism 
of action 50 
Degree of 
induction 
Time (hr) required 
to see DNA. synthesis 
inhibition (%) 
Btr 
HU 
FdUrd 
Thd 
MTX 
Ara-C 
BrdUrd 
Aph 
PFA 
Mit C 
Unknown 
Inhibit ribonucleotide 
diphosphate reductase 
Inhibit thymidylate 
synthetase 
Inhibit deoxyribonucleotide 
reductase 
Inhibit dihydrofolate 
reductase 
Inhibit DNA polymerase by 
competing with dCTP; 
incorporate into DNA causing 
chain termination 
Incorporate into DNA by 
competing with thymidine 
Inhibit DNA polymerase a 
Inhibit DNA polymerase a 
Forms cross-links to DNA 
1.9 mM 
1.6 mM 
3.5 
82 
1 . 2  
0 .8  
pM 
Vig/ml 
10.7 kig/ml 
0.1 n-g/ml 
0.225 mM 
30 |jM 
-f++ 
44-
++ 
12 (47%) 
3 (93%) 
6 (66%) 
3 (49%) 
72 (61%) 
12 (75%) 
3 (53%) 
3 (97%) 
3 (93%) 
6 (48%) 
Table X. Continued 
DNA synthesis 
inhibitor 
Suggested mechanism 
of action 5^0 
Degree of 
induction 
Time (hr) required 
to see DNA synthesis 
inhibition (%) 
Bleo React with DNA and causes 
strand scission 
10 mU/ml — 12 (68%) 
EB Intercalates between base 
pairs 
4 Wg/ml — 12 (84%) 
Mcr Results in a rapid frag­
mentation of DNA 
16. ,4 pg/ml — 6 (88%) 
Ces Unknown 1 ng/ml — 9 (83%) 
Acr Intercalates into DNA 75 MM — 12 (52%) 
I50 was the concentration of each DNA synthesis inhibitor causing 50% inhibition of DNA 
synthesis determined by reciprocal plot from concentration curve of each inducer. Degree of 
induction was designated as high inducer (144 I ), intermediate inducer (++ or 444-), low inducer (+•), 
or noninducer (-) depending on maximum fold induction of ectopic proteins shown in Figure 22 and 
Table II. Data of time and percent to see DNA. synthesis inhibition were derived from kinetics 
study of each inducer. 
125 
multiplication may play a role in modulation of gene expression. 
Since these two agents were synergistic with butyrate in promoting 
choriogonadotropin synthesis (56, 86, and Table VII), activation in 
tumor cells of genes normally expressed by fetal tissue and the 
consequent ectopic synthesis of polypeptide hormones by butyrate may 
require neither cell division nor DNA synthesis. 
Mechanism of Butyrate Action 
Butyrate has pleiotropic effects on a wide variety of cell types 
as reviewed by Prasad and Sinha (95). Recent studies on mammalian 
cells in culture suggest that sodium butyrate affects the morphology, 
growth rate, and biochemical properties of cells (96). Although 
sodium butyrate has been shown to produce an immediate, but gradual, 
decrease in DNA synthesis in HeLa cultures (125), it became ap­
parent that it produces many types of effects on these cells, and its 
role in cellular function is poorly understood. It is noteworthy 
that sodium butyrate, which alters HeLa cell morphology, inhibits 
their growth, and induces alkaline phosphatase, also mediates increased 
choriogonadotropin synthesis. The action of butyrate seems to be on 
several genetic loci, since several studies indicate that the synthesis 
of other glycoprotein tropic hormones such as follicle stimulating 
hormone (FSH) and lutenizing hormone (LH) also may be induced in 
HeLa cells by butyrate (117). 
It is suggested that sodium butyrate induced alkaline phospha­
tase through a direct mechanism at the transcriptional level in 
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choriocarcinoma cells where DNA synthesis is not affected and seems 
to be required for the induction. Furthermore, an increase in alka­
line phosphatase mRNA production could be demonstrated only in 
choriocarcinoma cells (243). Although sodium butyrate increases 
alkaline phosphatase activity in both HeLa and choriocarcinoma cells, 
two different mechanisms might be involved in the induction. 
Several groups have observed an increase in acetylated forms of 
histone H4 in cells exposed to butyrate (102, 103, 108, 244), and 
it has been proposed that this is due to inhibition of histone deacetyla-
tion (103, 244). Since modified histones have been associated in many 
instances with change in gene expression (245), it is possible that 
the fatty acid acts by direct gene activation. In hepatoma 
tissue culture (HTC) cells, however, the increased amount of histone 
acetylation is maximal 6-12 hr after administration of sodium butyrate, 
and protein patterns on two-dimensional gel electrophoresis showed that 
no different proteins were made during this period (107). It was sug­
gested that there is apparently no immediate cause and effect relation­
ship between hyperacetylation and major changes in gene expression at 
the translational level. But the possibility cannot be excluded that 
the extra margin of hyperacetylated histone might exert a highly 
deleterious effect on cell division. 
It is known that treatment of the cell with sodium butyrate 
significantly affects the structure and function of the cell membranes 
that are directly responsible for its morphology and growth rate. Sodium 
butyrate causes HeLa cells to assume a fibroblastic or spindle-like 
127 
morphology (246). Thus, it is of interest whether a possible re­
lationship between butyrate-mediated alterations in cell shape and 
increase in the activity of certain enzymes may exist. 
Several membrane-associated activities have been reported to be 
altered after HeLa cells were exposed to butyrate, including sialyltrans-
ferase (118), 5'-nucleotidase (246), acetylcholinesterase (246), cholera 
toxin receptors (120), and alkaline phosphatase (112). The activities 
of these membrane-bound polypeptides were increased except for that of 
acetylcholinesterase which was slightly reduced by butyrate. 
The alkaline phosphatase is a membrane-bound glycoprotein and both 
subunits of placental hCG are glycosylated, containing about 30% carbo­
hydrate (39, 247, 248). Tunicamycin (TM) and 2-deoxyglucose (dGlc) 
are known to inhibit the glycosylation of proteins (249, 250, 251, 
252). The effects of inhibiting protein glycosylation with TM and dGlc 
on the synthesis of alpha and PAP have been investigated to determine 
whether the tumor alpha protein is glycosylated and whether protein 
glycosylation is a prerequisite for secretion (253). The inhibition 
of alpha and PAP synthesis by dGlc and TM (though to a lesser extent) 
was generally greater in butyrate-treated cultures, indicating that the 
cells' response to butyrate is quite sensitive to these agents (254). 
Since butyrate has been shown to increase the activity of a sialyltrans-
ferase in HeLa cells (118) and the secretion of thyroglobulin has 
been shown to be enhanced by sialylation (255), it is possible that 
butyrate may be involved directly or indirectly to enhance the secre­
tion of glycoproteins. 
Sodium butyrate induced ectopic proteins in HeLa S3 cells without 
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interfering significantly with protein or RNA synthesis (Table III). 
Although increases in ectopic protein production in cells treated with 
sodium butyrate required synthesis of RNA and protein (Figure 23a), 
inhibition of DNA synthesis may be necessary but not sufficient for 
induction, since cell growth can be severely restricted without con­
comitant induction. Moreover, sodium butyrate causes synergistic effects 
on the induction by other DNA synthesis inhibitors. Although the 
synthesis of ectopic proteins can be increased in HeLa cells by 
butyrate, intermediate inducers (HU, FdUrd, etc.), and low inducers 
(BrdUrd), the mechanism of induction seems to differ among these com­
pounds. Thus, it is possible that sodium butyrate may act through altera­
tions in cellular functions other than the inhibition of DNA synthesis 
to produce ectopic proteins in HeLa cells. 
Inducers Other Than Sodium Butyrate 
In addition to sodium butyrate, several inhibitors of DNA synthesis 
are capable of inducing the ectopic proteins in HeLa cells even 
though the level of PAP and subunit are less than those produced by 
the fatty acid. This intermediate group of inducers, including HU, 
MTX, FdUrd, Thd, and ara-C, has a common, though not identical, effect 
on cellular function. They inhibit DNA synthesis by interfering with 
any one of several steps in the synthesis of deoxynucleotide precursors. 
Hydroxyurea inhibits DNA synthesis by inhibiting the ribonucleo­
tide reductase system, thereby depleting cells of deoxyribonucleotides 
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(128, 129). It inhibits reduction for each of the four common nucleo­
tides; GDP, ADP, UDP, and GDP. The deoxyribonucleotide reductase con­
version of GDP to dCDP is inhibited by thymidine (157). Thus, both agents 
inhibit reduction of ribonucleotides either one specific ribonucleotide 
or all four ribonucleotides. Another key step in the synthesis of deoxy-
nucleotides is the conversion of dUMP to dTMP. Thymidylate synthetase 
catalyzes this reaction by transfer of a 1-carbon unit from methylene 
tetrahydrofolic acid. 5-fluoro-2'-deoxyuridine inhibits thymidylate 
synthetase directly (159) and methotrexate acts by inhibiting dihydro-
folate reductase, thereby depriving thymidylate synthetase of a neces­
sary substrate (173). Although the specific substrate affected by these 
inhibitors is different from one another, they all deplete deoxyribo­
nucleotide pools causing inhibition of DNA synthesis. Since most of the 
good inducers share this property, that is, inhibiting dNTP metabolism, 
this could be a possible mechanism for induction rather than DNA inhibi­
tion per se. 
In an attempt to narrow the specificity of the inducers and to 
further investigate the possible relationship between ectopic protein 
induction and DNA synthesis inhibition, it was of interest to examine 
agents which directly inhibit eukaryotic DNA polymerase. In the present 
study, the effects of two such inhibitors, aphidicolin and phosphono-
formic acid, on the synthesis in HeLa cells of alkaline phosphatase 
and the glycoprotein hormone subunits were investigated. 
Aphidicolin is a tetracyclic diterpenoid (212) which has been 
shown to be a specific inhibitor of DNA polymerase a from several sources 
(220, 221, 222, 223, 224) but not DNA polymerase p or Y (220, 223, 225) 
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at levels which inhibit mitosis. The inhibition by aphidicolin of 
purified DNA polymerase a from sea urchins, adenovirus-infected KB 
cells, and HeLa cells was competitive with respect to dCTP, while DNA 
synthesis inhibition in isolated nuclei was noncompetitive with respect 
to all four dNTPs (215, 222, 224). 
Phosphonoformic acid has been shown to inhibit the replication 
of herpes simplex virus and to inhibit herpes virus-, vaccinia 
virus-, and adenovirus-induced DNA polymerases as well as DNA 
polymerase a from calf thymus and HeLa.(226, 227, 256, 257, 258). 
Ostrander and Cheng (257) and Eriksson et al. (227) have shown that 
the pyrophosphate analog is an uncompetitive inhibitor with respect to 
DNA and a noncompetitive inhibitor with respect to dNTPs. 
The results presented here demonstrate that the glycoprotein hor­
mone Of- and 8-subunits and placental type alkaline phosphatase are in­
duced in HeLa cells by the DNA polymerase a inhibitors, Aph and PFA. 
Although some variability was evident, the data suggested that in general 
the maximum induction of PAP was greater than that for the a- or p-
subunit in response to PFA (Figure 20), while the maximum induction of 
the hormone subunits was greater than that for PAP in response to Aph 
(Figure 18). Moreover, the immediate increase in Of-subunit concentra­
tions compared to the 24- or 48-hr lag required to observe an increase 
in the levels of PAP or P-subunit following the addition of Aph 
(Figures 19a and b) suggests that the induction of these ectopic 
products is not coordinate. Similarly, the maximum induction of PAP 
occurred several hours prior to that, of or or p-subunit in response 
to PFA (Figures 21a and b). 
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Even though there was no apparent lag in the accumulation of 
(y-subunit in the media of Aph- and PFA-treated cultures, the induction 
process seems dependent on continued RNA and protein synthesis 
since it was inhibited by actinomycin D and cycloheximide 
(Figures 23b and c). Production ceased abruptly in the presence of 
cycloheximide but continued at a slower rate for about 24 hr after the 
addition of actinomycin D. This could be interpreted as continued 
translation of pre-existing o-triRNA during this time period. 
The relationship of ectopic protein induction to DNA synthesis 
inhibition is unclear. As stated above, several agents which produce 
increased levels of PAP and hC6 in HeLa cells are known to inhibit DNA 
replication. However, the mechanism by which these compounds bring 
about increased ectopic protein synthesis is unknown, and a direct 
correlation between these processes has not been demonstrated. While 
induction of PAP and hCG in HeLa cells by butyrate and hydroxy urea 
is preceded by a 24-48 hr lag (Figure 5 and Figure 7), such a lag was 
not evident with Aph or PFA, except perhaps for the induction of PAP 
by Aph, suggesting that the DNA polymerase inhibitors are operating 
through a mechanism different from that of the above compounds. 
This is partly substantiated by the results presented in Tables 
VII and IX. Induction of ectopic products was synergistic (or 
at least additive) when Aph and PFA were added in combination with 
butyrate, suggesting different modes of action for these compounds 
(Table VII). In contrast, protein induction in the presence of Aph 
or PFA in combination with hydroxy urea was less than that in the 
presence of either inducer alone (Table IX) indicating similar or 
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competing mechanisms. 
Although it is tempting to speculate that PAP and hCG subunit 
induction results from the inhibition of DNA polymerase a by Aph and PFA, 
recent results published suggest that alternative interpretations are 
possible. Several aphidicolin-resistant (Aph^ ) mutant cell lines have 
been isolated (259, 260, 261, 262, 263). Characterization of these 
lines has shown that the Aph^  phenotype is often associated with in­
creased levels of deoxynucleoside triphosphates (259, 261) or increased 
ribonucleotide reductase activity (260, 262), and that few lines exhibit 
an altered DNA polymerase a or an increase in polymerase activity 
(263). Consequently, aphidicolin may significantly alter nucleotide 
pool sizes jji vivo (as do intermediate inducers) in addition to its 
effect on DNA polymerase in vitro. 
Though the kinetics of replication inhibition are consistent with 
those for protein induction (i.e., DNA synthesis was inhibited prior 
to increased protein accumulation), the fact that the concentration of 
Aph required to produce half-maximal induction of the a-subunit (1.5 
Hg/ml) was an order of magnitude higher than the concentration required 
to inhibit DNA synthesis by 50% (<0.1 pg/ml) (Tables X and XI) sug­
gests that the drug may have multiple sites of action and that linking 
ectopic protein induction with DNA polymerase inhibition may not be 
warranted. 
Within the intermediate and low inducer groups, ara-C and BrdUrd 
show somewhat different characteristics, Ara-C and BrdUrd are not 
good inducers for the ectopic proteins, and they did not give repro­
ducible results like most of the intermediate inducer group. The 
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reasons for this are unknown. However, they did not inhibit induction as 
did the DM synthesis inhibitors which alter DNA structure such as 
mitomycin C, bleomycin, ethidium bromide, acridine, macromomycin, and 
cesalin. 
In contrast to the good induction of PAP and hCG by BrdUrd in 
choriocarcinoma cells, it was a very poor inducer of these same pro­
teins in HeLa cells. As suggested above, alterations in nucleotide 
metabolism may play a key role in the induction process, though the 
mechanism by which increased ectopic protein synthesis occurs is unknown 
and a direct correlation between these processes has not been demonstrated. 
Consequently, the induction observed in response to ara-C and BrdUrd 
may be variable if these agents inhibit DNA synthesis by direct incorpora­
tion into DNA rather than by inhibiting dNTP synthesis. 
The results obtained in this study for the induction of hCG-a and 
-P in HeLa cells by ara-C are in agreement with the report by Ghosh 
et al. (156). However, Ruddon et al. (264) have reported that inhibition 
of cell proliferation per se with ara-C did not increase hCG-o? or hCG-p 
production in HeLa cells, nor did ara-C potentiate the effects of sub-
maximal concentrations of butyrate. Their results are in contrast to 
the present study and that of Ghosh et al. (156), who reported that 
hydroxyurea or ara-C alone induced hCG subunits in HeLa cells and that 
both drugs exhibited a synergistic effect on butyrate-induced hCG-a 
and -p secretion. Thus, they suggested that the mechanisms controlling 
the induction of gonadotropin subunit synthesis appear to be different 
in various HeLa strains. This is supported by the data of Chou (265), 
who examined the induction of hCG-a and hCG in a large number of HeLa 
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strains and found that sodium butyrate treatment increased hCG-o; 
synthesis in all strains whereas 5-bromodeoxyuridine increased hCG-a 
synthesis in about 85% of strains and usually to a much lower extent 
than did butyrate. 
The experiments presented in Table IX show that the simultaneous 
addition to cultures of various paired combinations of the intermediate 
inducers resulted in no greater induction than that observed with either 
drug alone, indicating similar or competing mechanisms for induction 
of ectopic proteins by these agents. The simultaneous addition of 
sodium butyrate and noninducing agents resulted in the inhibition of 
induction of ectopic proteins (Table VIII). Because RNA and protein 
syntheses are required for the induction, as shown by the effects of 
actinomycin D and cycloheximide on orsubunit induction (Figure 23), 
the block of RNA and protein synthesis caused by exposure to the non-
inducing agents (Table III) could affect the action of sodium butyrate. 
Correlation between Inhibition of DNA 
Synthesis and Protein Induction 
The inhibition of cell growth, the alteration in cell shape, and 
the increase of several proteins (including fetal alkaline phosphatase, 
hCG, and putative pituitary hormones FSH and LH) in HeLa cells suggests 
that butyrate may mediate its effects at a stage of the cell cycle where 
a number of different genetic loci are susceptible to activation. In 
support of this speculation, is the finding that several inhibitors of 
DNA synthesis also increase hCG synthesis (156) and oncofetal alkaline 
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phosphatase activity (155) and act synergistically with sodium butyrate. 
Even though little is known about the mechanism by which specialized 
synthetic programs are coupled to inhibition of DNA replication, the 
concentration curves and kinetics for induction by several DNA 
synthesis inhibitors may provide information on the more precise 
relationship of DNA synthesis inhibition to ectopic protein production. 
Results with the various DNA synthesis inhibitors on protein in­
duction are summarized in Table XI. Dose-response curves for sodium 
butyrate and several intermediate inducers showed that inhibition of 
DNA synthesis occurred at concentrations similar to those causing 
protein induction. That is, the values for DNA synthesis inhibi­
tion were more or less equivalent to the FI50 values for protein 
induction in response to Btr, HU, Thd, FdUrd, and ara-C. These results 
would be consistent with a cause and effect relationship between these 
two events. Moreover, kinetic experiments in general were also 
consistent with a correlation between ectopic protein induction and 
DNA synthesis inhibition in HeLa cultures (e.g.. Figures 13 and 15), 
though a precise correlation was not observed for all inducers. That 
is, the inhibition of DNA synthesis generally occurred prior to the 
induction of PAP and gonadotropin subunits. However, other possibilities 
cannot be ruled out. Several compounds showed a lag time to induce 
proteins and/or their concentrations required for inhibiting DNA synthesis 
were much less than those required for promoting induction. For exanqple, 
p-subunit was induced at 15, 48, or 72 hr after exposure to Btr, Aph, 
or BrdUrd, respectively. Even though a correlation could still be 
drawn in this case because the lag time might be necessary to induce 
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Table XI. Summary of effects of inducers on ectopic protein synthesis 
Max. 
Cone, giving induction 
Inducer Protein ^^ 50 max. induction T. (hr) fold 
Na-butyrate a 1.70 mM >4 mM 6 10.1 
P 2.44 3 15. 3.6 
PAP 1.34 >4 3-6 7.9 
Hydroxyurea a 0.74 mM >2 mM 3 2.6 
; 0.87 >2 mM 15-24 2.8 
PAP 0.18 0.5 6-12 2.0 
FdUrd a 1.78 pM 3.8 pM 3 3.7 
P 1.13 3.8 15 7.2 
PAP 0.80 2.6 3 1.5 
Thd a 56 |JM 0.15 mM 24 2.2 
P 139 — — 1.1 
PAP 25 0.2 3 5.0 
MTX a 0.67 pM 2 pM 12 2.5 
P 0.63 4 24 2.0 
PAP 0.10 1.6 3 2.9 
Ara-C a 0.48 (ig/ml 1 jxg/ml 12 1.3 
P 0.50 1 12-24 2.3 
PAP 1.28 2 3 2.3 
BrdUrd a 8.7 Hg/ml 20 Pg/ml 72 2.8 
P 12.8 30 72 7.5 
PAP 6.8 20 3-6 2.4 
Aph a 1.2 Pg/ml 5 Hg/ml 3 5.1 
B 3.6 10 48 5.2 
PAP 0.3 0.5 24-48 2.0 
PFA a 1.40 mM 2.5 mM 3 2.3 
P 1.30 1.8 3 3.2 
PAP 0.62 >3.1 3-6 7.7 
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Table XI. Continued 
FI50 was the concentration of each Inducer causing half maximum 
Induction of hormone subunlts and alkaline phosphatase. These values 
were calculated from double-reciprocal plots of dose-response 
determinations. Maximum Induction and the concentration of Inducers 
at which It occurred were also summarized from data of dose-response 
curves (Figure 4 through Figure 20, even numbered figures only). As 
shown in the kinetics experiments (Figure 5 through Figure 21, odd 
numbered figures only), hormone subunlts and alkaline phosphatase in­
creased the rate of production at a specific time for each protein 
after incubation and those were summarized as the time required to 
see induction (T^ ). 
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proteins in some cell lines, a significant lag time between inhibition 
of replication and the maximal rate of induction could indicate that the 
effect of DNA synthesis inhibition on protein induction is indirect. 
This same argument can be made even for the reagents that exhibit no 
lag time but have I^ Q values for DNA synthesis that are much lower 
than the for protein induction (PAP by ara-C, ohsubunit by Aph, 
and a-i B-subunits and PAP by PFA). Thus, it may be possible that 
DNA synthesis inhibition is, in part, a requirement for the induction 
of ectopic products. Nevertheless, the fact that not all inhibitors, 
of DNA synthesis lead to increased synthesis of hCG and PAP suggests 
that DNA synthesis inhibition may be required but is not sufficient 
for this process. 
Noncoordinate Regulation of Ectopic Proteins 
in HeLa Cells 
Although sodium butyrate and intermediate inducers caused the in­
crease of hCG-cy and subunits as well as the activity of alkaline 
phosphatase, the concentrations producing maximum induction for the 
individual proteins were not the same in some Instances (HU, MTX, Aph, 
PFA). Moreover, the concentrations of agents required to produce half 
maximal induction were not the same for each protein and the patterns 
of induction were not consistent; that is, the Flgg values for crsubunit 
production by FdUrd, MTX, and PFA were greater than those for p-subunit 
or PAP while those for other inducers were just the opposite. 
As shown in the time course experiments and Table XI, the kinetics 
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of induction differed from one protein to another; some inducers (such 
as HU and Aph) caused crsubunit production earlier than PAP production, 
while other inducers (including Thd, MIX, ara-C, and BrdUrd) produced 
increases in PAP earlier than a-subunit. The production of hCG-a or 
PAP, in general, preceded that of hCG-p; increases of hCG-a or PAP 
occurred about 3 to 6 hr after inducer addition while about 15 to 24 
hr was required for hCG-p induction. Taken together, these results 
suggest that the regulation of ectopic synthesis is not coordinated 
in HeLa cells, and even though these proteins are synthesized ectopically 
as a group, the synthesis of each protein may be regulated differently. 
Comparison of Human Chorionic Gonadotropin and Placental 
Alkaline Phosphatase in Nontrophoblastic and Trophoblastic Tumors 
Since alkaline phosphatase and hCG are ectopic products for HeLa 
(nontrophoblastic tumor) but eutopic products for choriocarcinoma 
(trophoblastic tumor), the secretion of these proteins in the two cell 
types may be regulated differently. Although the effects of sodium 
butyrate are similar in most mammalian cells, it has strikingly dif­
ferent effects on these two classes of tumors; it induces the synthesis 
of hCG-a in nontrophoblastic tumor cells but represses its synthesis 
in trophoblastic tumor cells (110, 266, 267), even though both tumor 
types can produce hCG-a in the absence of inducer. Moreover, DNA 
synthesis in HeLa cells is inhibited by exposure to sodium butyrate for 
24 hr (98, 110, and Table III) , whereas DNA synthesis in choriocarcinoma 
cells is not affected (110). Sodium butyrate slightly enhanced the 
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incorporation of thymidine in JEG-3 choriocarcinoma cells but transiently 
inhibited the incorporation in HeLa cells, although the long-term 
effects seemed to be the same for both types of tumor cells. It is 
suggested that inhibition of DNA synthesis may play a role in the in­
duction of hCG-a synthesis even though the mechanism of sodium butyrate 
is not known. 
While alkaline phosphatase can be induced by c-AMP in chorio­
carcinoma cells (266), compounds such as xanthine, caffeine, and theo­
phylline (which increased intracellular cyclic AMP concentrations) 
inhibited the induction of alkaline phosphatase by IdUrd or hydro­
cortisone (112, 268) as well as by NaCl, choline chloride, or sodium 
butyrate (269) in HeLa cells. It may be speculated that c-AMP is 
somehow involved in the inhibition of induction by these compounds, 
since all may potentially increase the concentration of c-AMP in HeLa 
cells (161). However, the role of cyclic AMP as a causative agent in 
regulating alkaline phosphatase activity is still uncertain since it 
has opposite effects on enzyme induction in trophoblastic and nontropho-
blastic tumor cell cultures. 
The effects of dibutyryl cyclic AMP (dbc AMP) and theophylline (T) 
on secretion of hCG and its subunits were essentially reversed, compared 
to the effects of butyrate, in both the trophoblastic and nontropho-
blastic cells (266, 267). Thus, dbc AMP plus T caused a dramatic (up 
to 250-fold) stimulation of hCG and both subunits in trophoblastic 
cells or placenta, but caused less than a 2-fold stimulation of hCG-3 
secretion by nontrophoblastic cells. These findings suggest that the 
differential effects of dbc AMP and butyrate on trophoblastic and 
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nontrophoblastic cells reflect differences in the transcription or 
translation of these genes in the two cell types. Furthermore, the 
mechanism of alkaline phosphatase induction by sodium butyrate may 
also differ in choriocarcinoma and HeLa cells since an increase in 
alkaline phosphatase mRNA production could be demonstrated only in 
choriocarcinoma cultures (243). 
There is also an apparent difference between eutopic and ectopic 
hCG-producing lines with respect to the kinetics of hormone secretion. 
The rate of secretion of the Of-subunit by ChaGo bronchogenic carcinoma 
cells is somewhat slower than that by JAR choriocarcinoma cells as 
determined by pulse-chase labeling techniques (270), even though the 
intracellular precursor forms of hCG subunits are similar in eutopic 
and ectopic hCG-producing cell lines (270, 271). 
It has been reported that alkaline phosphatase is induced in. cul­
tured human choriocarcinoma cells by three inhibitors of DNA synthesis 
which alter DNA structure: 1-P-D-arabinofuranosylcytosine, mitomycin 
C, and phleomycin. No induction is observed with the inhibitors 
hydroxyurea and thymidine, which inhibit deoxynucleotide synthesis 
but do not alter DNA. configuration (125). In contrast to that report, 
however, the results in the present study with HeLa Sg cells were just 
the opposite. Those compounds that do not alter DNA structure but in­
fluence the metabolism of deoxynucleotide precursors induced ectopic 
proteins, while the inhibitors of DNA synthesis which cause DNA struc­
tural alterations did not induce. It is suggested that these compounds 
which do not act as inducers not only inhibited cellular DNA replication 
but also inhibited RNA and protein synthesis in HeLa S3 cells during 
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exposure to these agents for 24 hr. 
The results from the experiment with actinomycln D and cyclo-
heximide suggest that the syntheses of RNA and protein are required 
for the induction of crsubunit and PAP in HeLa cells (Figures 23a, 
b, and c). Thus, this requirement may explain why the DNA synthesis 
inhibitors which cause a concomitant inhibition of RNA and protein 
synthesis do not induce ectopic proteins in this cell line (Tables 11 
and 111). In choriocarcinoma cells DNA replication was completely 
inhibited in the presence of compounds which alter DNA structure; 
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ara-C stopped the uptake of [methyl- H] thymidine within 24 hr, 
whereas mitomycin C and phleomycin stopped it in 72 hr. The rates 
3 3 
of incorporation of [ H] leucine and [ H] uridine were not altered 
by exposure of cultures to these compounds for 24 hr, though long expo­
sure (3 days) of cells to these inhibitors reduced the rates of both 
protein and RNA synthesis (30-50% for protein synthesis and 15-50% 
for RNA synthesis). It suggests that synthesis of hCG and PAP up to 
3 days incubation with these compounds is not affected by the reduced 
protein and RNA synthesis in choriocarcinoma cells, while exposure of 
HeLa cells to these compounds results in a more immediate inhibition 
of RNA and protein synthesis (within 24 hr) and may prevent induction 
of the ectopic products. Thus, as long as RNA, and protein synthesis 
were not severely inhibited, these compounds resulted in increased 
alkaline phosphatase and chorionic gonadotropin production in choriocarci­
noma cells. It is interesting that these structure-altering compounds 
have such a different effect on the rate at which RNA and protein 
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syntheses are inhibited in the trophoblastic and nontrophoblastic tumor 
cell lines. The reasons for this are unknown. 
Characterization of Induced Proteins 
The existence of a large immunologic species of hCG-a subunit in 
the placenta has been described (115, 116, 272). It is possible that 
the large hCG-crlike material produced by transformed placental cells 
was a precursor form of hCG-#, as speculated by Weintraub et al. (28). 
Although relatively large quantities of hCG-o and hCG-p were synthesized 
by transformed placental cells, little native hCG was produced (33). 
It is possible that the lack of native hCG might reflect structural 
defects in the subunits. In the present study, serial dilutions of 
HeLa tissue culture media exactly paralleled dilutions of urinary hCG-a 
in the standard radioimmunoassay, indicating virtual immunological 
identity (27 and Figure 24). Data presented in Table IV demonstrate 
that the crsubunits induced by several compounds also produced slopes 
similar to that of standard hCG-a. Similar results have been reported 
in the dose response curves for holo hCG in both radioreceptorassay 
(RRA) and radioimmunoassay (RIA) which would indicate similarities in 
biological activity and in immunological determinants (33). However, 
the apparent molecular weight of the HeLa cr subunit as determined by 
gel filtration is greater than that of urinary hCG-of. Lieblich et al. 
(27) have suggested that the HeLa protein may represent a precursor 
form which is left unprocessed by the tumor cells. However, Cox (273) 
has recently reported that the HeLa protein coelutes with the urinary 
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subunit following mild acid hydrolysis. These results suggest that 
the ectopic product differs from its placental counterpart in sialic 
acid content. 
There is extensive evidence that human alkaline phosphatase exists 
in multiple forms and that the forms found in different organs possess 
distinct properties by which they may be recognized (75). Alkaline 
phosphatase activity in placental cells was repressed by transforma­
tion (choriocarcinoma cells) in contrast to the selective activation of 
placental phosphatase in many human tumors (274). Herz (204) has sug­
gested that the inducible form of the enzyme corresponds to the human 
fetal form, whereas the repressible enzyme may be the product of the 
same gene which produces kidney alkaline phosphatase. In addition, 
this kind of heterogeneity in alkaline phosphatase has been observed 
for the intestinal enzyme during various developmental stages (61). 
Moreover, the activity of heterogeneous alkaline phosphatases (both 
heat-stable and heat-labile) are increased by enzyme inducers such as 
sodium butyrate or IdUrd in human choriocarcinoma cells (87). It has 
also been reported that the alkaline phosphatases in untreated and 
sodium butyrate-treated choriocarcinoma cells resembled the term 
placental enzyme in immunochemical reactivity and pH optimum but were 
less stable to heating than was the term placental alkaline phospha­
tase (243). 
The results reported here show that the alkaline phosphatases in 
HeLa cells exposed to a wide range of inducers resemble the term 
placental enzyme with respect to their thermostability and inhibition 
profile in response to several effectors. 
145 
Ectopic Synthesis and Clinical Applications 
The inappropriate synthesis by tumors of specialized proteins and 
polypeptides normally produced by differentiated cells or at a particular 
stage of embryonic development provides a potential model for investigating 
the control of gene expression and for elucidating some aspects of 
neoplastic transformation. 
The production of the placental proteins hCG and PAP by a 
nontrophoblastic tumor cell is unexpected and suggests that the 
genome of HeLa cells is derepressed for highly differentiated gene 
products since templates for the synthesis of these polypeptides 
are present in a dormant, repressed state in the genome of all 
cells (275). Support for this hypothesis comes from the findings that 
similarities at the molecular level have been observed between the normal 
and ectopic hormones (118, 276, 277). The ectopic secretion by tumors 
is probably the manifestation of an activation or derepression of genetic 
information which should ordinarily be inactive. Most if not all neo­
plasms, regardless of their adult tissue of origin, apparently re-
express genes associated with embryonic developmental structures ap­
pearing as early as the trophoblast. It is suggested that permanent 
reexpression of the early developmental genes may be necessary to main­
tain malignancy. 
However, Yoshimoto et al. (278) proposed another hypothesis 
for ectopic synthesis of polypeptides. They have reported that 
by means of two assay systems (RIA and REA), a chorionic gonado­
tropin- like substance was demonstrated in extracts of liver and colon 
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obtained at autopsy from patients who died of nonneoplastic disease. 
In contrast to placental chorionic gonadotropin, colon and liver chorionic 
gonadotropin were not bound to concanavalin A-Sepharose columns, 
indicating that this substance possessed little or no carbohydrate. 
The data suggest that the genes responsible for the human chorionic 
gonadotropin production are not completely suppressed in adult non-
endocrine tissues, and that the chorionic gonadotropin produced by 
colon and liver has little or no bioactivity in vivo because of its 
low carbohydrate content. Since normal tissues can produce chorionic ; 
gonadotropin, bioactivity may be modulated by regulation of carbohydrate 
content. Moreover, several laboratories have demonstrated the hetero­
geneity of glycoprotein hormones and their subunits (116, 272, 279). 
They suggested that this heterogeneity of the hCG-a produced by non-
trophoblastic tumor cells might be due to variations in their carbo­
hydrate moieties. 
Some anti-neoplastic drugs which are specific inhibitors of DNA 
but not RNA synthesis in HeLa S^  cells increase the activity of onco-
foetal alkaline phosphatase and hCG synthesis. The finding that butyrate 
and other DNA synthesis inhibitors also stimulate ectopic protein pro­
duction suggests that inhibition of DNA synthesis or cell multiplica­
tion may have a role in modulating gene expression. Although little is 
known about the mechanism by which specialized synthetic programs are 
coupled to inhibition of DNA synthesis, the acquisition of a differentiated 
phenotype in a number of tissues including muscle, cartilage, nervous 
system, and others is preceded by the cessation of cell prolifera­
tion (280, 281). The ectopic synthesis of trophoblastic proteins by 
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neoplastic cells may require neither cell division nor DNA replication. 
These findings may have important implications for studies on neoplasia. 
The different responses to various DNA synthesis inhibitors also 
indicate that the regulation of protein production differs in tropho­
blastic and nontrophoblastic tumors. Thus, detailed analysis of the 
molecular mechanisms underlying the biosynthesis of these proteins 
by these cell lines may yield insight into the essential nature of 
ectopic protein production. 
As stated in the Introduction, protein hormones and other poly­
peptides may be produced ectopically by malignant tumors derived from 
nonendocrine tissues or endocrine tissues other than those that nor­
mally produce these products. Much attention has been focused on the 
placental proteins hCG and placental lactogen whose presence in the 
serum of a man or nonpregnant woman has been considered virtually 
diagnostic of neoplasm. These placental proteins, it appears, may be 
used as tumor markers only in a quantitative sense. Thus, increased 
circulating levels of p, or hCG in the plasma of a patient with 
neoplasm argues strongly for malignancy. 
The fall in hCG during the course of chemotherapy for gestational 
choriocarcinoma is one of the oldest and, perhaps, the most specific 
examples of using a biochemical marker as an index of tumor cell 
destruction (282). As such, it represents a significant achievement in 
chemotherapy by offering an assessment of clinical progress and an end 
point of chemotherapy. However, in certain cases where tumors may 
synthesize the proteins in quantities too small to cause elevated 
plasma levels, it is hard to use ectopic proteins as specific 
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Indicators of malignancy or to discern the progress of tumorIgenlclty. 
Thus, compounds such as butyrate and other Inhibitors of DNA, synthesis 
(FdUrd, MTX, etc.) may have application In the detection of occult 
malignancies. If they can activate the production of tumor "marker" 
proteins In early neoplasms, they may facilitate the diagnosis of some 
cancers prior to onset of symptoms. Moreover, their administration 
to patients following surgery or chemotherapy of a primary lesion 
may lead to the earlier detection of unsuspected metastasis. Obviously, 
this is an important area that requires further investigation. 
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APPENDIX 
Figure 26. Structures of several DNA synthesis inhibitors 
a. Phosphonoformic acid 
b. Aphidicolin 
c. Macromomycin 
d. Bleomycin A.; C-atoms are indicated with numbers 
(C-l-C-55) and N-àtoms with characters (N-a-N-i, 
N-k-N-n, N-p, N-r-N-t) 
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Table XII. Solvent other than distilled H^ O for several DNA 
synthesis inhibitors 
Inhibitor Solvent 
MTX 0.01 N NaOH and neutralized with conc. HCl 
Acridine Ethanol 
Cesalin 0.1% BSA in PBS 
Aph DMSG (dimethylsulfoxide) 
PFA 0.1% Tween 80 and 10% (W/W) glycerol in 
HgO, adjusted pH 6.0 with HCl or NaOH 
